TW201811791A - 新穎[1,2,3]三唑并[4,5-d]嘧啶衍生物 - Google Patents
新穎[1,2,3]三唑并[4,5-d]嘧啶衍生物 Download PDFInfo
- Publication number
- TW201811791A TW201811791A TW106120830A TW106120830A TW201811791A TW 201811791 A TW201811791 A TW 201811791A TW 106120830 A TW106120830 A TW 106120830A TW 106120830 A TW106120830 A TW 106120830A TW 201811791 A TW201811791 A TW 201811791A
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- triazolo
- phenyl
- pyrimidin
- difluoropyrrolidin
- Prior art date
Links
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title claims description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- -1 Isothiocyano Chemical group 0.000 claims description 229
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 217
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 107
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 52
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 39
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims description 31
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 27
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 25
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 claims description 16
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 claims description 16
- 206010016654 Fibrosis Diseases 0.000 claims description 16
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 16
- 206010020751 Hypersensitivity Diseases 0.000 claims description 14
- 230000007815 allergy Effects 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 12
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 11
- 230000004761 fibrosis Effects 0.000 claims description 11
- 208000020016 psychiatric disease Diseases 0.000 claims description 11
- 208000002193 Pain Diseases 0.000 claims description 10
- 206010063837 Reperfusion injury Diseases 0.000 claims description 10
- 206010003246 arthritis Diseases 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 208000001132 Osteoporosis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 206010014599 encephalitis Diseases 0.000 claims description 8
- 208000026278 immune system disease Diseases 0.000 claims description 8
- 201000004792 malaria Diseases 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 7
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 6
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 6
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 6
- 208000032544 Cicatrix Diseases 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 208000002260 Keloid Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 231100000836 acute liver failure Toxicity 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 208000007565 gingivitis Diseases 0.000 claims description 6
- 230000001969 hypertrophic effect Effects 0.000 claims description 6
- 230000007574 infarction Effects 0.000 claims description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 6
- 210000001117 keloid Anatomy 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 201000002793 renal fibrosis Diseases 0.000 claims description 6
- 231100000241 scar Toxicity 0.000 claims description 6
- 230000037387 scars Effects 0.000 claims description 6
- 150000003573 thiols Chemical class 0.000 claims description 6
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 6
- LRWSSHQGKKWDLU-UHFFFAOYSA-N 3-[[5-[difluoro(phenyl)methyl]-7-[3-(methyldisulfanyl)pyrrolidin-1-yl]triazolo[4,5-d]pyrimidin-3-yl]methyl]-4-methyl-1,2,5-oxadiazole Chemical compound CSSC1CCN(C1)C1=NC(=NC2=C1N=NN2CC1=NON=C1C)C(F)(F)C1=CC=CC=C1 LRWSSHQGKKWDLU-UHFFFAOYSA-N 0.000 claims description 5
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims description 5
- 201000001200 Crouzon syndrome-acanthosis nigricans syndrome Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 230000007882 cirrhosis Effects 0.000 claims description 5
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- YLPSAOYZKVCQKO-UHFFFAOYSA-N 2-[[5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]benzenesulfonyl fluoride Chemical compound FC(C=1N=C(C2=C(N=1)N(N=N2)CC1=C(C=CC=C1)S(=O)(=O)F)N1CC(CC1)(F)F)(C1=CC=CC=C1)F YLPSAOYZKVCQKO-UHFFFAOYSA-N 0.000 claims description 4
- CQXMBSLTHDMGIM-UHFFFAOYSA-N CCCCC1=NC=C2C(=N1)N(N=N2)CC3=NON=C3C Chemical compound CCCCC1=NC=C2C(=N1)N(N=N2)CC3=NON=C3C CQXMBSLTHDMGIM-UHFFFAOYSA-N 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 230000001434 glomerular Effects 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- YJKDCZLPIBOXFJ-UHFFFAOYSA-N CCCCC1=NC=C2C(=N1)N(N=N2)CC3=CC=CC=C3Cl Chemical compound CCCCC1=NC=C2C(=N1)N(N=N2)CC3=CC=CC=C3Cl YJKDCZLPIBOXFJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004146 Propane-1,2-diol Substances 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 3
- IDIPWEYIBKUDNY-UHFFFAOYSA-N benzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=CC=CC=C1 IDIPWEYIBKUDNY-UHFFFAOYSA-N 0.000 claims description 3
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 3
- OIBMEBLCOQCFIT-UHFFFAOYSA-N ethanesulfonyl fluoride Chemical compound CCS(F)(=O)=O OIBMEBLCOQCFIT-UHFFFAOYSA-N 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- IJXLXBBOFXRJGE-IBGZPJMESA-N (3S)-1-[5-[difluoro(phenyl)methyl]-3-[[2-(isothiocyanatomethyl)phenyl]methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound O[C@H]1CCN(C1)C1=NC(=NC2=C1N=NN2CC1=C(CN=C=S)C=CC=C1)C(F)(F)C1=CC=CC=C1 IJXLXBBOFXRJGE-IBGZPJMESA-N 0.000 claims description 2
- XLERKZZJDZBXGG-UHFFFAOYSA-N 3-[(2-chlorophenyl)methyl]-5-[difluoro(phenyl)methyl]-7-(3-isothiocyanatopyrrolidin-1-yl)triazolo[4,5-d]pyrimidine Chemical compound ClC1=C(C=CC=C1)CN1N=NC2=C1N=C(N=C2N1CC(CC1)N=C=S)C(C1=CC=CC=C1)(F)F XLERKZZJDZBXGG-UHFFFAOYSA-N 0.000 claims description 2
- WODTUUKLNRBZQF-UHFFFAOYSA-N 3-[[5-[difluoro(phenyl)methyl]-7-(3-isothiocyanatopyrrolidin-1-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]-4-methyl-1,2,5-oxadiazole Chemical compound CC1=NON=C1CN1N=NC2=C1N=C(N=C2N1CCC(C1)N=C=S)C(F)(F)C1=CC=CC=C1 WODTUUKLNRBZQF-UHFFFAOYSA-N 0.000 claims description 2
- OBQBUVKMGGTBTF-UHFFFAOYSA-N 5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)-3-[(2-isothiocyanatophenyl)methyl]triazolo[4,5-d]pyrimidine Chemical compound FC(F)(C1=CC=CC=C1)C1=NC2=C(N=NN2CC2=C(C=CC=C2)N=C=S)C(=N1)N1CCC(F)(F)C1 OBQBUVKMGGTBTF-UHFFFAOYSA-N 0.000 claims description 2
- AYAQSHBRTCYTRR-UHFFFAOYSA-N 5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)-3-[[2-(isothiocyanatomethyl)phenyl]methyl]triazolo[4,5-d]pyrimidine Chemical compound FC(F)(C1=CC=CC=C1)C1=NC2=C(N=NN2CC2=C(CN=C=S)C=CC=C2)C(=N1)N1CCC(F)(F)C1 AYAQSHBRTCYTRR-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 claims description 2
- 241000219094 Vitaceae Species 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 235000021021 grapes Nutrition 0.000 claims description 2
- KVTUSMPNLUCCQO-UHFFFAOYSA-N 3,3-difluoropyrrolidine Chemical compound FC1(F)CCNC1 KVTUSMPNLUCCQO-UHFFFAOYSA-N 0.000 claims 1
- DZJLSSOKZFTBON-UHFFFAOYSA-N CCC1=C(C2=C(C=C1)C3=CC=CC=C3C2)S(=O)(=O)O Chemical compound CCC1=C(C2=C(C=C1)C3=CC=CC=C3C2)S(=O)(=O)O DZJLSSOKZFTBON-UHFFFAOYSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- KSSNDBTVZHMEJL-UHFFFAOYSA-N chloroimino(sulfanylidene)methane Chemical compound ClN=C=S KSSNDBTVZHMEJL-UHFFFAOYSA-N 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 147
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 85
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 84
- 239000000203 mixture Substances 0.000 description 83
- 235000019439 ethyl acetate Nutrition 0.000 description 73
- 239000002585 base Substances 0.000 description 69
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 238000003818 flash chromatography Methods 0.000 description 37
- 239000000377 silicon dioxide Substances 0.000 description 37
- 239000012141 concentrate Substances 0.000 description 34
- 235000008504 concentrate Nutrition 0.000 description 34
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
- 239000012267 brine Substances 0.000 description 31
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 239000012230 colorless oil Substances 0.000 description 29
- 239000002904 solvent Substances 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 17
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 16
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 15
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 14
- 238000012746 preparative thin layer chromatography Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 150000001540 azides Chemical group 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000000556 agonist Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- WBILDQZWYMFRNR-UHFFFAOYSA-N 3-methyl-1,2,5-oxadiazole Chemical compound CC=1C=NON=1 WBILDQZWYMFRNR-UHFFFAOYSA-N 0.000 description 7
- 239000005909 Kieselgur Substances 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 5
- JSXBJYJOHVHWSW-UHFFFAOYSA-N CCCCN1C2=C(C(=NC=N2)N3CCC(C3)(F)F)N=N1 Chemical compound CCCCN1C2=C(C(=NC=N2)N3CCC(C3)(F)F)N=N1 JSXBJYJOHVHWSW-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 5
- 239000012964 benzotriazole Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Substances SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 5
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 4
- FRZHZQYEXCBWEM-UHFFFAOYSA-N 1-(chloromethyl)-2-(isothiocyanatomethyl)benzene Chemical compound ClCC1=C(CN=C=S)C=CC=C1 FRZHZQYEXCBWEM-UHFFFAOYSA-N 0.000 description 4
- ZXRSVNNZHVTXIL-UHFFFAOYSA-N 2,2-difluoro-2-phenylacetonitrile Chemical compound N#CC(F)(F)C1=CC=CC=C1 ZXRSVNNZHVTXIL-UHFFFAOYSA-N 0.000 description 4
- AMOYMEBHYUTMKJ-UHFFFAOYSA-N 2-(2-phenylethoxy)ethylbenzene Chemical compound C=1C=CC=CC=1CCOCCC1=CC=CC=C1 AMOYMEBHYUTMKJ-UHFFFAOYSA-N 0.000 description 4
- HNQMOKGNUUFCBS-UHFFFAOYSA-N 2-[2-[2-[[5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]phenyl]ethyldisulfanyl]ethanol Chemical compound FC(C=1N=C(C2=C(N=1)N(N=N2)CC1=C(C=CC=C1)CCSSCCO)N1CC(CC1)(F)F)(C1=CC=CC=C1)F HNQMOKGNUUFCBS-UHFFFAOYSA-N 0.000 description 4
- PDNUZSJRBFQRIB-UHFFFAOYSA-N 5-amino-1-[(2-ethenylphenyl)methyl]triazole-4-carboxamide Chemical compound NC(=O)C1=C(N)N(CC2=C(C=C)C=CC=C2)N=N1 PDNUZSJRBFQRIB-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 4
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 229910019213 POCl3 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- CNKGPJREXAOQCB-UHFFFAOYSA-N diazonio(pyrrolidin-3-yl)azanide Chemical compound [N-]=[N+]=NC1CCNC1 CNKGPJREXAOQCB-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011698 potassium fluoride Substances 0.000 description 4
- 235000003270 potassium fluoride Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- LLHVKCNTLXMIRO-UHFFFAOYSA-N 1-(azidomethyl)-2-(chloromethyl)benzene Chemical compound N(=[N+]=[N-])CC1=C(C=CC=C1)CCl LLHVKCNTLXMIRO-UHFFFAOYSA-N 0.000 description 3
- TVRHFPPPDGPSSP-UHFFFAOYSA-N 1-[5-[difluoro(phenyl)methyl]-3-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidine-3-thiol Chemical compound CC1=NON=C1CN1N=NC2=C1N=C(N=C2N1CCC(S)C1)C(F)(F)C1=CC=CC=C1 TVRHFPPPDGPSSP-UHFFFAOYSA-N 0.000 description 3
- INOGLHRUEYDAHX-UHFFFAOYSA-N 1-chlorobenzotriazole Chemical compound C1=CC=C2N(Cl)N=NC2=C1 INOGLHRUEYDAHX-UHFFFAOYSA-N 0.000 description 3
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 3
- YYVPZQADFREIFR-UHFFFAOYSA-N 3,3-difluoropyrrolidine;hydrochloride Chemical compound [Cl-].FC1(F)CC[NH2+]C1 YYVPZQADFREIFR-UHFFFAOYSA-N 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 3
- YNHMYRUNFIQMPN-UHFFFAOYSA-N 5-amino-1-[(2-chlorophenyl)methyl]triazole-4-carboxamide Chemical compound NC1=C(C(=O)N)N=NN1CC1=CC=CC=C1Cl YNHMYRUNFIQMPN-UHFFFAOYSA-N 0.000 description 3
- UJTGWCMHPZTDEE-UHFFFAOYSA-N 7-chloro-5-[difluoro(phenyl)methyl]-3-[(2-ethenylphenyl)methyl]triazolo[4,5-d]pyrimidine Chemical compound FC(F)(C1=CC=CC=C1)C1=NC2=C(N=NN2CC2=C(C=C)C=CC=C2)C(Cl)=N1 UJTGWCMHPZTDEE-UHFFFAOYSA-N 0.000 description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 3
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 3
- ZBYZPHGCWGNVKZ-UHFFFAOYSA-N CC1=NON=C1CN1N=NC2=C1NC(=NC2=O)C(F)(F)C1=CC=CC=C1 Chemical compound CC1=NON=C1CN1N=NC2=C1NC(=NC2=O)C(F)(F)C1=CC=CC=C1 ZBYZPHGCWGNVKZ-UHFFFAOYSA-N 0.000 description 3
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 229930003827 cannabinoid Natural products 0.000 description 3
- 239000003557 cannabinoid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002621 endocannabinoid Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002530 ischemic preconditioning effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 3
- RYCUILMYNOQRAZ-UHFFFAOYSA-N pyrrolidin-3-yl methanesulfonate hydrochloride Chemical compound Cl.CS(=O)(=O)OC1CCNC1 RYCUILMYNOQRAZ-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- FMGGHNGKHRCJLL-UHFFFAOYSA-N 1,2-bis(chloromethyl)benzene Chemical compound ClCC1=CC=CC=C1CCl FMGGHNGKHRCJLL-UHFFFAOYSA-N 0.000 description 2
- RTIRHCXJRGZELP-UHFFFAOYSA-N 1-(bromomethyl)-2-isothiocyanatobenzene Chemical compound BrCC1=CC=CC=C1N=C=S RTIRHCXJRGZELP-UHFFFAOYSA-N 0.000 description 2
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N 2,3-dimethylpyridine Chemical compound CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MAYMYMXYWIVVOK-UHFFFAOYSA-N 2-[(4,6-dimethoxypyrimidin-2-yl)carbamoylsulfamoyl]-4-(methanesulfonamidomethyl)benzoic acid Chemical compound COC1=CC(OC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=C(CNS(C)(=O)=O)C=2)C(O)=O)=N1 MAYMYMXYWIVVOK-UHFFFAOYSA-N 0.000 description 2
- GFIIGVXBVCZZNB-UHFFFAOYSA-N 2-[2-[[5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]phenyl]ethanethiol Chemical compound FC(F)(C1=CC=CC=C1)C1=NC2=C(N=NN2CC2=C(CCS)C=CC=C2)C(=N1)N1CCC(F)(F)C1 GFIIGVXBVCZZNB-UHFFFAOYSA-N 0.000 description 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- NUPLLTDVHPEUQM-UHFFFAOYSA-N 2-cyanoethanimidamide Chemical compound NC(=N)CC#N NUPLLTDVHPEUQM-UHFFFAOYSA-N 0.000 description 2
- BVNNLACXKMUKRA-UHFFFAOYSA-N 3-[[7-(3-azidopyrrolidin-1-yl)-5-[difluoro(phenyl)methyl]triazolo[4,5-d]pyrimidin-3-yl]methyl]-4-methyl-1,2,5-oxadiazole Chemical compound CC1=NON=C1CN1N=NC2=C1N=C(N=C2N1CCC(C1)N=[N+]=[N-])C(F)(F)C1=CC=CC=C1 BVNNLACXKMUKRA-UHFFFAOYSA-N 0.000 description 2
- HDIIRFSDOGZVGS-UHFFFAOYSA-N 3-[[7-chloro-5-[difluoro(phenyl)methyl]triazolo[4,5-d]pyrimidin-3-yl]methyl]-4-methyl-1,2,5-oxadiazole Chemical compound CC1=NON=C1CN1N=NC2=C1N=C(N=C2Cl)C(F)(F)C1=CC=CC=C1 HDIIRFSDOGZVGS-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- LJQINJOCKBNGAJ-UHFFFAOYSA-N 3-bromo-2-methylbenzenesulfonyl chloride Chemical compound CC1=C(Br)C=CC=C1S(Cl)(=O)=O LJQINJOCKBNGAJ-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- AAZMQRIYWPPFCQ-UHFFFAOYSA-N 5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)-3-[(2-ethenylphenyl)methyl]triazolo[4,5-d]pyrimidine Chemical compound FC(F)(C1=CC=CC=C1)C1=NC2=C(N=NN2CC2=C(C=C)C=CC=C2)C(=N1)N1CCC(F)(F)C1 AAZMQRIYWPPFCQ-UHFFFAOYSA-N 0.000 description 2
- ZDNCRGRISMPFCG-UHFFFAOYSA-N 5-amino-1-[(2-benzylsulfanylphenyl)methyl]triazole-4-carboxamide Chemical compound NC1=C(N=NN1CC1=C(C=CC=C1)SCC1=CC=CC=C1)C(=O)N ZDNCRGRISMPFCG-UHFFFAOYSA-N 0.000 description 2
- VKYHTRPCVDIQOW-UHFFFAOYSA-N 5-amino-1-[(2-iodophenyl)methyl]triazole-4-carboxamide Chemical compound NC(=O)C1=C(N)N(CC2=C(I)C=CC=C2)N=N1 VKYHTRPCVDIQOW-UHFFFAOYSA-N 0.000 description 2
- SWRLPCRGGSVVQP-UHFFFAOYSA-N 5-amino-1-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]triazole-4-carboxamide Chemical compound NC1=C(N=NN1CC1=NON=C1C)C(=O)N SWRLPCRGGSVVQP-UHFFFAOYSA-N 0.000 description 2
- WKZVMRGKYCSXII-UHFFFAOYSA-N 7-(3-azidopyrrolidin-1-yl)-3-[(2-chlorophenyl)methyl]-5-[difluoro(phenyl)methyl]triazolo[4,5-d]pyrimidine Chemical compound FC(F)(C1=CC=CC=C1)C1=NC2=C(N=NN2CC2=C(Cl)C=CC=C2)C(=N1)N1CCC(C1)N=[N+]=[N-] WKZVMRGKYCSXII-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- GBJALSVMQPKVAQ-UHFFFAOYSA-N C(CCC)C=1N=C(C2=C(N1)N(N=N2)CC2=C(C=CC=C2)Cl)Cl Chemical compound C(CCC)C=1N=C(C2=C(N1)N(N=N2)CC2=C(C=CC=C2)Cl)Cl GBJALSVMQPKVAQ-UHFFFAOYSA-N 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101001116937 Homo sapiens Protocadherin alpha-4 Proteins 0.000 description 2
- 101001116931 Homo sapiens Protocadherin alpha-6 Proteins 0.000 description 2
- 239000005577 Mesosulfuron Substances 0.000 description 2
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- ZZQZQWLVDBHHKV-UHFFFAOYSA-N [2-(bromomethyl)phenyl]methanesulfonyl fluoride Chemical compound BrCC1=C(C=CC=C1)CS(=O)(=O)F ZZQZQWLVDBHHKV-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WKVAOKPPTCPUEU-UHFFFAOYSA-N azetidine-3-thiol;hydrochloride Chemical compound Cl.SC1CNC1 WKVAOKPPTCPUEU-UHFFFAOYSA-N 0.000 description 2
- UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000005997 bromomethyl group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical group CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- XUPLQGYCPSEKNQ-UHFFFAOYSA-H hexasodium dioxido-oxo-sulfanylidene-lambda6-sulfane Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=S.[O-]S([O-])(=O)=S.[O-]S([O-])(=O)=S XUPLQGYCPSEKNQ-UHFFFAOYSA-H 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical compound NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 2
- 150000003512 tertiary amines Chemical group 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- BHBIPLOIWQSVID-UHFFFAOYSA-N thiohypofluorous acid Chemical compound SF BHBIPLOIWQSVID-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000000287 tissue oxygenation Effects 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- NLSRPTWDWDKYOB-UHFFFAOYSA-N (2-iodophenyl)methanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1I NLSRPTWDWDKYOB-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JGTNAGYHADQMCM-UHFFFAOYSA-M 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F JGTNAGYHADQMCM-UHFFFAOYSA-M 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- PUCGLIPZQDGVKF-UHFFFAOYSA-N 1-chloro-1,2-diphenylethanethiol Chemical compound SC(Cl)(Cc1ccccc1)c1ccccc1 PUCGLIPZQDGVKF-UHFFFAOYSA-N 0.000 description 1
- GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical compound CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 1
- WDBAXYQUOZDFOJ-UHFFFAOYSA-N 2,3-difluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1F WDBAXYQUOZDFOJ-UHFFFAOYSA-N 0.000 description 1
- GVEUHELYYABRSJ-UHFFFAOYSA-N 2-[2-[2-[[5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]phenyl]ethyldisulfanyl]ethanamine Chemical compound FC(C=1N=C(C2=C(N=1)N(N=N2)CC1=C(C=CC=C1)CCSSCCN)N1CC(CC1)(F)F)(C1=CC=CC=C1)F GVEUHELYYABRSJ-UHFFFAOYSA-N 0.000 description 1
- ADHRHPCQANGIMU-INIZCTEOSA-N 2-[[5-[difluoro(phenyl)methyl]-7-[(3S)-3-hydroxypyrrolidin-1-yl]triazolo[4,5-d]pyrimidin-3-yl]methyl]benzenesulfonyl fluoride Chemical compound FC(C=1N=C(C2=C(N=1)N(N=N2)CC1=C(C=CC=C1)S(=O)(=O)F)N1C[C@H](CC1)O)(C1=CC=CC=C1)F ADHRHPCQANGIMU-INIZCTEOSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- CUBIPASREFIVNT-UHFFFAOYSA-N 2-tert-butyl-3-methylsulfonyloxypyrrolidine-1-carboxylic acid Chemical compound CC(C)(C)C1C(OS(C)(=O)=O)CCN1C(O)=O CUBIPASREFIVNT-UHFFFAOYSA-N 0.000 description 1
- QWYTUBPAXJYCTH-UHFFFAOYSA-N 2-trimethylsilylethyl carbamate Chemical compound C[Si](C)(C)CCOC(N)=O QWYTUBPAXJYCTH-UHFFFAOYSA-N 0.000 description 1
- OSKSVLBJJXQUPI-UHFFFAOYSA-N 2h-triazole-4-carboxamide Chemical compound NC(=O)C1=CNN=N1 OSKSVLBJJXQUPI-UHFFFAOYSA-N 0.000 description 1
- UXZGHLGMWLCYLX-UHFFFAOYSA-N 3-[[5-[difluoro(phenyl)methyl]-7-[3-(methyldisulfanyl)pyrrolidin-1-yl]triazolo[4,5-d]pyrimidin-3-yl]methyl]-4-methyl-1,2,5-oxadiazole methyl methanesulfonate Chemical compound S(C)(=O)(=O)OC.FC(C=1N=C(C2=C(N1)N(N=N2)CC2=NON=C2C)N2CC(CC2)SSC)(C2=CC=CC=C2)F UXZGHLGMWLCYLX-UHFFFAOYSA-N 0.000 description 1
- TUMNKJQPLNKBBH-UHFFFAOYSA-N 3-[[7-(3-azidopyrrolidin-1-yl)-5-tert-butyltriazolo[4,5-d]pyrimidin-3-yl]methyl]-4-methyl-1,2,5-oxadiazole Chemical compound CC1=NON=C1CN1N=NC2=C1N=C(N=C2N1CCC(C1)N=[N+]=[N-])C(C)(C)C TUMNKJQPLNKBBH-UHFFFAOYSA-N 0.000 description 1
- IWTYTFSSTWXZFU-UHFFFAOYSA-N 3-chloroprop-1-enylbenzene Chemical compound ClCC=CC1=CC=CC=C1 IWTYTFSSTWXZFU-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- OKUZMJNEJUATOH-UHFFFAOYSA-N 5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)-3-[[2-[2-(pyridin-2-yldisulfanyl)ethyl]phenyl]methyl]triazolo[4,5-d]pyrimidine Chemical compound FC(C=1N=C(C2=C(N=1)N(N=N2)CC1=C(C=CC=C1)CCSSC1=NC=CC=C1)N1CC(CC1)(F)F)(C1=CC=CC=C1)F OKUZMJNEJUATOH-UHFFFAOYSA-N 0.000 description 1
- GOKSVNXOWOMVOS-UHFFFAOYSA-N 5-tert-butyl-7-(3,3-difluoropyrrolidin-1-yl)-3-[(2-isothiocyanatophenyl)methyl]triazolo[4,5-d]pyrimidine Chemical compound CC(C)(C)C1=NC2=C(N=NN2CC2=C(C=CC=C2)N=C=S)C(=N1)N1CCC(F)(F)C1 GOKSVNXOWOMVOS-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- SCGORAJGRKNBSY-UHFFFAOYSA-N 9h-fluorene-1-sulfonic acid Chemical group C1C2=CC=CC=C2C2=C1C(S(=O)(=O)O)=CC=C2 SCGORAJGRKNBSY-UHFFFAOYSA-N 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229910016264 Bi2 O3 Inorganic materials 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 101150106726 Cnr2 gene Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- FARDXTMJUIJFEE-UHFFFAOYSA-N F.ClN1C(CCC1=O)=O Chemical compound F.ClN1C(CCC1=O)=O FARDXTMJUIJFEE-UHFFFAOYSA-N 0.000 description 1
- XMNMJLZZBKPJHI-UHFFFAOYSA-N FC(F)(C1=CC=CC=C1)C1=NC(=O)C2=C(N1)N(CC1=C(C=C)C=CC=C1)N=N2 Chemical compound FC(F)(C1=CC=CC=C1)C1=NC(=O)C2=C(N1)N(CC1=C(C=C)C=CC=C1)N=N2 XMNMJLZZBKPJHI-UHFFFAOYSA-N 0.000 description 1
- BTSGNVZFNOJZSC-UHFFFAOYSA-N FC(F)(C1=CC=CC=C1)C1=NC(=O)C2=C(N1)N(CC1=C(SCC3=CC=CC=C3)C=CC=C1)N=N2 Chemical compound FC(F)(C1=CC=CC=C1)C1=NC(=O)C2=C(N1)N(CC1=C(SCC3=CC=CC=C3)C=CC=C1)N=N2 BTSGNVZFNOJZSC-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000012407 Inhibin-beta Subunits Human genes 0.000 description 1
- 108010061971 Inhibin-beta Subunits Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- XMZWONFJBZKVFW-UHFFFAOYSA-N N(=C=S)C1CN(CC1)N1N=NC2=C1N=CN=C2 Chemical compound N(=C=S)C1CN(CC1)N1N=NC2=C1N=CN=C2 XMZWONFJBZKVFW-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- HLYYQKPJZQRNGG-UHFFFAOYSA-N N1=CC(=CC=C1)N.N1C=CC=C1 Chemical compound N1=CC(=CC=C1)N.N1C=CC=C1 HLYYQKPJZQRNGG-UHFFFAOYSA-N 0.000 description 1
- 229910021204 NaH2 PO4 Inorganic materials 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- DYWUGKXPDFYJOD-UHFFFAOYSA-N S-[1-[5-[difluoro(phenyl)methyl]-3-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-yl] ethanethioate Chemical compound C(C)(SC1CN(CC1)C=1C2=C(N=C(N=1)C(C1=CC=CC=C1)(F)F)N(N=N2)CC1=NON=C1C)=O DYWUGKXPDFYJOD-UHFFFAOYSA-N 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- WBRXOEFAJMYPQS-UHFFFAOYSA-N [2-[[5-[difluoro(phenyl)methyl]-7-(3,3-difluoropyrrolidin-1-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]phenyl]methanesulfonyl fluoride Chemical compound FC(F)(C1=CC=CC=C1)C1=NC2=C(N=NN2CC2=C(CS(F)(=O)=O)C=CC=C2)C(=N1)N1CCC(F)(F)C1 WBRXOEFAJMYPQS-UHFFFAOYSA-N 0.000 description 1
- XZEOQRFGNMLPGH-SFHVURJKSA-N [2-[[5-[difluoro(phenyl)methyl]-7-[(3S)-3-hydroxypyrrolidin-1-yl]triazolo[4,5-d]pyrimidin-3-yl]methyl]phenyl]methanesulfonyl fluoride Chemical compound O[C@H]1CCN(C1)C1=NC(=NC2=C1N=NN2CC1=C(CS(F)(=O)=O)C=CC=C1)C(F)(F)C1=CC=CC=C1 XZEOQRFGNMLPGH-SFHVURJKSA-N 0.000 description 1
- 238000010958 [3+2] cycloaddition reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- CMANTJGPMZJEQC-UHFFFAOYSA-N benzylsulfanium;fluoride Chemical compound [F-].[SH2+]CC1=CC=CC=C1 CMANTJGPMZJEQC-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- XNNQFQFUQLJSQT-UHFFFAOYSA-N bromo(trichloro)methane Chemical compound ClC(Cl)(Cl)Br XNNQFQFUQLJSQT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000056964 human CNR1 Human genes 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- FQZMFQBVDCQBBL-UHFFFAOYSA-N n,n-dimethylmethanamine;trihydrofluoride Chemical compound F.F.F.CN(C)C FQZMFQBVDCQBBL-UHFFFAOYSA-N 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- CQGGPYGGOANVNO-UHFFFAOYSA-N o-(2-phenylethyl) ethanethioate Chemical compound CC(=S)OCCC1=CC=CC=C1 CQGGPYGGOANVNO-UHFFFAOYSA-N 0.000 description 1
- UIGFNSQASSOFIJ-UHFFFAOYSA-N o-benzyl benzenecarbothioate Chemical compound C=1C=CC=CC=1C(=S)OCC1=CC=CC=C1 UIGFNSQASSOFIJ-UHFFFAOYSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000003157 protein complementation Methods 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- ZIFNUUAXASKDJT-UHFFFAOYSA-N sulfanium;benzene;fluoride Chemical compound [F-].[SH3+].C1=CC=CC=C1 ZIFNUUAXASKDJT-UHFFFAOYSA-N 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 125000005190 thiohydroxy group Chemical group 0.000 description 1
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
本發明係關於對2型大麻素(CB2)受體具有親和力之新穎[1,2,3]三唑并[4,5-d]嘧啶衍生物,其製法及其診斷與治療用途。
大麻素受體為一類屬於G蛋白-偶聯受體超家族之細胞膜受體。目前存在兩種已知亞型,稱為大麻素受體1 (CB1)及大麻素受體2 (CB2)。該CB1受體主要於中樞神經(即杏仁核小腦、海馬體)系統中表現及於週邊中表現較少量。由CNR2基因編碼之CB2主要在諸如巨噬細胞及T-細胞之免疫系統細胞(Ashton, J. C.等人,Curr Neuropharmacol 2007, 5(2), 73-80;Miller, A. M.等人,Br J Pharmacol 2008, 153(2), 299-308;Centonze, D.等人,Curr Pharm Des 2008, 14(23), 2370-42)及於胃腸系統(Wright, K. L.等人. Br J Pharmacol 2008, 153(2), 263-70)中週邊地表現。該CB2受體亦廣泛地分佈於腦中,其主要發現於小膠質細胞而非神經元(Cabral, G. A.等人,Br J Pharmacol 2008, 153(2): 240-51)。 大麻素受體2之調節劑可用於哺乳動物之治療及/或預防。 由於若干早期化合物顯示出於針對許多包括慢性疼痛(Beltramo, M. Mini Rev Med Chem 2009, 9(1), 11-25)、動脈粥樣硬化(Mach, F.等人,J Neuroendocrinol 2008, 20增刊1, 53-7)、骨質調節(Bab, I.等人,Br J Pharmacol 2008, 153(2), 182-8)、神經性炎症(Cabral, G. A.等人,J Leukoc Biol 2005, 78(6), 1192-7)、局部缺血/再灌注損傷(Pacher, P.等人,Br J Pharmacol 2008, 153(2), 252-62)、全身性纖維化(Akhmetshina, A.等人,Arthritis Rheum 2009, 60(4), 1129-36;Garcia-Gonzalez, E.等人,Rheumatology (牛津大學) 2009, 48(9), 1050-6)、肝纖維化(Julien, B.等人,Gastroenterology 2005, 128(3), 742-55;Munoz-Luque, J. 等人,J Pharmacol Exp Ther 2008, 324(2), 475-83)之人類疾病之臨床前模型中具有有益作用之事實,在過去十年期間對CB2受體激動劑之關注在穩定上升(目前30至40例患者應用/年)。 局部缺血/再灌注(I/R)損傷為發生於諸如中風、心肌梗塞、心肺繞道術及其他血管外科手術及器官移植之狀況下之組織損傷的主要原因以及併發各種病因的循環休克過程之末梢器官損傷之主要機理。所有該等狀況以正常血液供應中斷導致不足的組織氧合為特徵。例如再灌注之再氧合為最終治療以恢復正常組織氧合。然而來自血液之氧及營養素之缺乏創造狀況,該狀況中循環的恢復導致進一步的組織損傷。再灌注損傷之損害部分由於受損組織之發炎反應。由新回血攜帶至區域之白細胞響應於組織損傷而釋放多種諸如白細胞介素之炎症因子以及自由基。該恢復之血流再引入細胞內之氧,其損害細胞蛋白質、DNA及質膜。 遠端局部缺血預處理(RIPC)代表用於利用體內抗由局部缺血及再灌注引起之損傷的內源性保護能力的策略。該遠端局部缺血預處理描述有趣的現象,其中一個器官或組織之短暫非致死性局部缺血及再灌注賦予於遠端器官或組織中隨後的「致死性」局部缺血性再灌注損傷發作。雖然已提出了若干假設,但目前未知器官或組織之短暫局部缺血及再灌注賦予保護之真實機理。 體液假說提出於遠端器官或組織中產生之內源性物質(諸如腺苷、緩激肽、類鴉片、CGRP、內源性大麻素、血管收縮素I或一些其他還未識別之體液因子)進入血流及活化靶組織中各自之受體及從而募集於局部缺血預處理中涉及之心肌保護之各種細胞內路徑。 最新資料表明內源性大麻素及其受體,尤其CB2可涉及預處理及藉由發炎反應之下調有助於預防再灌注損傷(Pacher, P.等人,Br J Pharmacol 2008, 153(2), 252-62)。具體而言,使用CB2工具激動劑之最新研究證實用於減少以下器官中之I/R損傷之該概念的功效:心臟(Defer, N.等人,Faseb J 2009, 23(7), 2120-30)、腦(Zhang, M.等人,J Cereb Blood Flow Metab 2007, 27(7), 1387-96)、肝(Batkai, S.等人,Faseb J 2007, 21(8), 1788-800)及腎(Feizi, A.等人,Exp Toxicol Pathol 2008, 60(4-5), 405-10)。 此外,在過去幾年,日益增長的文獻表明CB2於亞慢性及慢性情境中可亦受關注。已顯示於與纖維化相關聯之慢性疾病之動物模型中(Garcia-Gonzalez, E. 等人,Rheumatology (牛津大學) 2009, 48(9), 1050-6;Yang, Y. Y.等人,Liver Int 2009, 29(5), 678-85),CB1及CB2之特異上調係與肌成纖維細胞中CB2之相關表現相關聯,該等細胞負責纖維化進展。 實際上已顯示藉由選擇性CB2激動劑激活CB2受體於彌漫全身性硬化症中發揮抗纖維化作用(Garcia-Gonzalez, E.等人,Rheumatology (牛津大學) 2009, 48(9), 1050-6)且CB2受體已成為於以下中之關鍵目標:實驗真皮纖維化(Akhmetshina, A.等人,Arthritis Rheum 2009, 60(4), 1129-36)及包括與慢性肝疾病相關聯之纖維發生之肝臟病理生理學(Lotersztajn, S.等人,Gastroenterol Clin Biol 2007, 31(3), 255-8;Mallat, A.等人,Expert Opin Ther Targets 2007, 11(3), 403-9;Lotersztajn, S.等人,Br J Pharmacol 2008, 153(2), 286-9)。 大麻素受體2之反向激動劑可用於哺乳動物之治療及/或預防。 式(I)之化合物特定可用於疼痛、神經痛、哮喘、骨質疏鬆症、炎症、精神性疾病、精神病、腫瘤學、腦炎、瘧疾、過敏症、免疫學病症、關節炎、胃腸疾病、精神疾病、類風濕性關節炎、精神病及過敏症之治療或預防。 在過去十年期間對CB2受體配位體之關注穩步上升(目前30至40篇專利申請/年)。不同來源之證據支持經由CB2受體的脂質內源性大麻素信號傳導代表哺乳動物保護醫療設備之一個態樣的觀點(Pacher, P. Prog Lipid Res 2011, 50, 193)。藉由選擇性CB2受體激動劑或反向激動劑/拮抗劑之其之調節(取決於疾病及其階段)於多數疾病中保持獨特的治療潛力。已證實CB2反向激動劑/拮抗劑用於包括以下之許多病理學病狀之治療機會:疼痛(Pasquini, S. J Med Chem 2012, 55(11):5391)、神經痛(Garcia-Gutierrez, M.S. Br J Pharmacol 2012, 165(4):951)、精神疾病(Garcia-Gutierrez, M.S. Br J Pharmacol 2012, 165(4):951)、精神病(Garcia-Gutierrez, M.S. Br J Pharmacol 2012, 165(4):951)、骨質疏鬆症及炎症(Sophocleous, A. Calcif Tissue Int 2008, 82(增刊1):Abst OC18)、精神性疾病及精神病(Garcia-Gutierrez, M.S. Br J Pharmacol 2012, 165(4):951)、腫瘤學(Preet, A. Cancer Prev Res 2011, 4:65)、腦炎及瘧疾(Zimmer, A.,WO 2011045068)、過敏症及炎症(Ueda, Y. Life Sci 2007, 80(5):414)、哮喘(Lunn, C.A. J Pharmacol Exp Ther 2006, 316(2):780)、免疫學病症(Fakhfouri, G. Neuropharmacology 2012, 63(4):653)、類風濕性關節炎(Chackalamannil, S. US 7776889)、關節炎(Lunn, C.A. J Pharmacol Exp Ther 2006, 316(2):780)及胃腸疾病(Barth, F. FR 2887550)。 本發明之化合物結合及調節該CB2受體且具有較低的CB1受體活性。 本發明之化合物包含視情況可用於與CB2受體形成共價鍵之(諸如)磺醯氟、異硫氰基、硫醇、疊氮化物及甲基二硫基之官能基。該等有機小分子作為共價修飾劑可用於靶之探測及定位化,以用於成像及用於治療用途(比較例如Adebayo A Adeniyi, Ramesh Muthusamy & Mahmoud ES Soliman, Expert Opin. Drug Discov. (2016) 11(1):79-90)。
本發明尤其係關於一種式(I)之化合物,(I) 其中 R1
為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自鹵磺醯基、鹵磺醯基烷基、異硫氰基烷基、異硫氰基、胺基烷基二硫基烷基、羥烷基二硫基烷基、羥烷基二硫基、胺基烷基二硫基、鹵素、烷基、吡啶基二硫基烷基、苯并三唑基磺醯基烷基、二羥烷基二硫基烷基及吡啶基二硫基之一個取代基取代及視情況進一步經氰基取代; R2
及R3
係獨立地選自氫、羥基、鹵素、硫羥基、硫羥基氮雜環丁烷基、疊氮基、異硫氰基及烷基二硫基; 其限制條件為R1
、R2
及R3
中至少一者為含有磺醯基、異硫氰基、二硫基、硫羥基或疊氮基之基團; R4
為烷基或及苯基鹵烷基;及 n為0或1; 或其醫藥上可接受的鹽或酯。 已發現對大麻素(CB2)受體具有高親和力及大選擇性之新穎[1,2,3]三唑并[4,5-d]嘧啶衍生物。該等化合物對CB2受體之活性具有調節效應。術語「調節效應」尤其意指激動劑、拮抗劑及/或反向激動劑效應。 大麻素受體2之激動劑可用於哺乳動物之治療及/或預防。式(I)之化合物特定可用於治療或預防(例如)疼痛、動脈粥樣硬化、年齡相關之黃斑變性、糖尿病性視網膜病、青光眼、糖尿病、炎症、炎性腸病、局部缺血再灌注損傷、急性肝衰竭、肝纖維化、肺纖維化、腎纖維化、全身性纖維化、急性同種異體移植排斥、慢性同種異體移植腎病、糖尿病性腎病、腎小球性腎病、心肌病、心臟衰竭、心肌缺血/梗塞、全身性硬化病、燙傷、燒傷、肥厚性瘢痕、瘢痕瘤、齦炎發熱、肝硬化或腫瘤、骨質調節、神經退化、中風、短暫性腦缺血發作或葡萄膜炎。 大麻素受體2之反向激動劑可用於哺乳動物之治療及/或預防。 式(I)之化合物特定可用於治療或預防疼痛、神經痛、哮喘、骨質疏鬆症、炎症、精神性疾病、精神病、腫瘤學、腦炎、瘧疾、過敏症、免疫學病症、關節炎、胃腸疾病、精神疾病及類風濕性關節炎。
本描述中單獨或於組合中之術語「烷基」意指具有1至8個碳原子之直鏈或分支鏈烷基,特定言之具有1至6個碳原子之直鏈或分支鏈烷基及更特定言之具有1至4個碳原子之直鏈或分支鏈烷基。直鏈及分支鏈C1
-C8
烷基之實例為甲基、乙基、丙基、異丙基、丁基、異丁基、第三丁基、異構戊基、異構己基、異構庚基及異構辛基,特定言之甲基、乙基、丙基、丁基及戊基。烷基之特定實例為甲基、乙基及第三丁基。 單獨或於組合中之術語「鹵素」或「鹵」意指氟、氯、溴或碘及特定言之氟、氯或溴,更特定言之氟或氯。與另一基團組合之術語「鹵」表示該基團經至少一個鹵素取代,特定言之經一至五個鹵素取代,特定言之一至四個鹵素,即一個、兩個、三個或四個鹵素。 單獨或於組合中之術語「鹵烷基」表示經至少一個鹵素取代的烷基,特定言之經一至五個鹵素取代,特定言之一至三個鹵素。特定「鹵烷基」為二氟甲基。 單獨或於組合中之術語「羥基(hydroxyl/hydroxy)」意指-OH基團。 單獨或於組合中之術語「胺基」意指一級胺基(-NH2
)、二級胺基(-NH-)或三級胺基(-N-)。 單獨或於組合中之術語「磺醯基」意指-SO2
基團。 單獨或於組合中之術語「二硫基」意指-S-S-基團。 單獨或於組合中之術語「異硫氰基」意指-N=C=S基團。 單獨或於組合中之術語「硫羥基(thiohydroxyl/thiohydroxy)」意指-SH基團。 單獨或於組合中之術語「疊氮基」意指-N3
基團。 術語「醫藥上可接受之鹽」係指保留游離鹼或游離酸之生物有效性及性質且通常在生物學上或其他方面係理想的鹽。與(諸如)鹽酸、氫溴酸、硫酸、硝酸、磷酸,特定言之鹽酸之無機酸及(諸如)乙酸、丙酸、乙醇酸、丙酮酸、草酸、馬來酸、丙二酸、琥珀酸、富馬酸、酒石酸、檸檬酸、苯甲酸、肉桂酸、杏仁酸、甲磺酸、乙磺酸、對甲苯磺酸、水楊酸、N-乙醯半胱胺酸之有機酸形成該等鹽。此外可自無機鹼或有機鹼與游離酸之加成製備該等鹽。衍生自無機鹼之鹽包括但不限於鈉鹽、鉀鹽、鋰鹽、胺鹽、鈣鹽、鎂鹽。衍生自有機鹼之鹽包括但不限於一級、二級及三級胺、包括天然存在的經取代之胺之經取代之胺、環胺及鹼性離子交換樹脂(諸如異丙胺、三甲胺、二乙胺、三乙胺、三丙胺、乙醇胺、離胺酸、精胺酸、N-乙基哌啶、哌啶、聚胺樹脂)之鹽。式(I)之化合物亦可以兩性離子形式存在。特別佳的式(I)之化合物之醫藥上可接受之鹽為鹽酸、氫溴酸、硫酸、磷酸及甲磺酸之鹽。 「醫藥上可接受之酯」意指通式(I)之化合物可在官能基上衍生化以提供能於活體內轉化回母體化合物之衍生物。該等化合物之實例包括(諸如)甲氧基甲基酯、甲硫基甲基酯及特戊醯甲基酯之生理學上可接受的及代謝不穩定的酯衍生物。此外,類似於代謝不穩定酯,能於活體內生成通式(I)之母體化合物之通式(I)之化合物之任何生理學上可接受的等效物係於本發明之範疇內。 若起始物質或式(I)之化合物之一包含一個或多個在一個或多個反應步驟之反應條件下不穩定的或具反應性的官能基,則可在關鍵步驟之前應用此項技術中熟知之方法引入適宜保護基(如(例如)由T. W. Greene及P. G. M. Wuts之「Protective Groups in Organic Chemistry」第3版,1999, Wiley, New York中所述)。可在合成之後期使用文獻中所述之標準方法移除該等保護基。保護基之實例為第三丁氧羰基(Boc)、胺基甲酸9-茀基甲基酯(Fmoc)、胺基甲酸2-三甲基甲矽烷基乙基酯(Teoc)、苄氧羰基(Cbz)及對甲氧苄氧羰基(Moz)。 式(I)之化合物可包含若干不對稱中心及可以光學純對映異構體、諸如(例如)外消旋物之對映異構體之混合物、非對映異構體之混合物、非對映異構外消旋物或非對映異構外消旋物之混合物之形式存在。 術語「不對稱碳原子」意指具有四個不同取代基的碳原子。根據Cahn-Ingold-Prelog規定,不對稱碳原子可為「R」或「S」構型。 本發明尤其係關於式(I)之化合物,其中 R1
為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自鹵磺醯基、鹵磺醯基烷基、異硫氰基烷基、異硫氰基、胺基烷基二硫基烷基、羥烷基二硫基烷基、羥烷基二硫基、胺基烷基二硫基、鹵素及烷基之一個取代基取代; R2
及R3
係獨立地選自氫、羥基、鹵素、硫羥基、硫羥基氮雜環丁烷基、疊氮基、異硫氰基及烷基二硫基; 其限制條件為R1
、R2
及R3
中至少一者為含有磺醯基、異硫氰基、二硫基、硫羥基或疊氮基之基團; R4
為烷基或苯基鹵烷基;及 n為0或1; 或其醫藥上可接受的鹽或酯。 本發明進一步係關於: 式(I)之化合物,其中R1
為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自鹵磺醯基、鹵磺醯基烷基、異硫氰基烷基、異硫氰基、鹵素及烷基之一個取代基取代; 式(I)之化合物,其中R1
為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自氟磺醯基、氟磺醯基甲基、異硫氰基甲基、異硫氰基、氯及甲基之一個取代基取代; 式(I)之化合物,其中R1
為氟磺醯基苯基、氟磺醯基甲基苯基、異硫氰基甲基苯基、異硫氰基苯基、氯苯基及甲基[1,2,5]噁二唑基; 式(I)之化合物,其中R2
為氫且R3
為羥基、硫羥基、疊氮基、異硫氰基或甲基二硫基或R2
及R3
同時均為氟; 式(I)之化合物,其中R4
為第三丁基或苯基二氟甲基;及 式(I)之化合物,其中n為1; 式(I)之化合物,其中R1
為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自鹵磺醯基、鹵磺醯基烷基、異硫氰基烷基、異硫氰基、鹵素、烷基、羥烷基二硫基烷基、吡啶基二硫基烷基、二羥烷基二硫基烷基之一個取代基取代及視情況進一步經氰基取代。 式(I)之化合物,其中R1
為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自氟磺醯基、氟磺醯基甲基、異硫氰基甲基、異硫氰基、氯、甲基、羥乙基二硫基乙基、氟磺醯基乙基、吡啶基二硫基乙基、二羥乙基二硫基乙基之一個取代基取代及視情況進一步經氰基取代;及 式(I)之化合物,其中R1
為氟磺醯基苯基、氟磺醯基甲基苯基、異硫氰基甲基苯基、異硫氰基苯基、氯苯基、甲基[1,2,5]噁二唑基、羥乙基二硫基乙基苯基、氟磺醯基乙基苯基、吡啶基二硫基乙基苯基、二羥乙基二硫基乙基苯基或(氟磺醯基)(氰基)苯基。 本發明進一步係關於選自以下之式(I)之化合物: 2-({5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯-1-磺醯氟; (2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲磺醯氟; [2-({5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]甲磺醯氟; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶; (3S)-1-(5-第三丁基-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[(2-異硫氰基苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯-1-磺醯氟; 2-{[(2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲基]二硫基}乙-1-胺; 2-{[(2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲基]二硫基}乙-1-醇; 2-[(2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)二硫基]乙-1-醇; 2-[(2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)二硫基]乙-1-胺; 2-{[2-({5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]二硫基}乙-1-胺; 2-({[2-({5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]甲基}二硫基)乙-1-胺; 2-({5-[二氟(苯基)甲基]-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯-1-磺醯氟; 2-({5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯-1-磺醯氟; [2-({5-[二氟(苯基)甲基]-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]甲磺醯氟; [2-({5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]甲磺醯氟; (3S)-1-(5-[二氟(苯基)甲基]-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇; 5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-[(2-異硫氰基苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; 1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}氮雜環丁烷-3-硫醇; (3S)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; (3R)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; (3S)-1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; (3R)-1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇 7-(3-疊氮吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-第三丁基-3-[(2-氯苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-第三丁基-7-(3-異硫氰基吡咯啶-1-基)-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 7-(3-疊氮吡咯啶-1-基)-5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 7-(3-疊氮吡咯啶-1-基)-5-[二氟(苯基)甲基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 7-(3-疊氮吡咯啶-1-基)-3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-[二氟(苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 2-[[5-[二氟(苯基)甲基]-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟; 2-[[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]甲基二硫基]乙醇; 2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟; 5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶; 2-[2-[2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇; 2-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇; 3-[[2-[2-(苯并三唑-1-基磺醯基)乙基]苯基]甲基]-5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶; 2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙磺醯氟; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶; 2-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙胺; 2-[2-[2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙胺; 3-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]丙烷-1,2-二醇; 2-[[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]二硫基]乙醇; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[[2-(吡啶-2-基二硫基)苯基]甲基]三唑并[4,5-d]嘧啶;及 2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]-3-乙炔基苯磺醯氟。 本發明亦關於選自以下之式(I)之化合物: 2-({5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯-1-磺醯氟; (2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲磺醯氟; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶; (3S)-1-(5-第三丁基-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[(2-異硫氰基苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯-1-磺醯氟; 1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; (3S)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; 7-(3-疊氮吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-第三丁基-7-(3-異硫氰基吡咯啶-1-基)-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 7-(3-疊氮吡咯啶-1-基)-3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟; 2-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇; 2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙磺醯氟; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶; 3-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]丙烷-1,2-二醇;及 2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]-3-乙炔基苯磺醯氟。 本發明之式(I)之化合物可依連續途徑或匯集合成途徑製備。以下反應圖顯示本發明之化合物之合成法。用於進行反應及純化所得產物所需之技能為熟習此項技術者已知。除非有相反的說明,否則用於以下方法之描述之取代基及標誌具有在本文之前給出的意義。更詳細而言,可藉由以下給出的方法,藉由實例中給出的方法或藉由類似方法製備式(I)之化合物。用於個別反應步驟之適宜反應條件為熟習此項技術者已知。另外,關於文獻中所述之實現所述反應之反應條件參見(例如):Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 第 2 版, Richard C. Larock. John Wiley & Sons, New York, NY. 1999) 。
吾人發現方便在存在或不存在溶劑下進行反應。對採用之溶劑之性質無特別限制,只要其對反應或相關試劑無不利影響及其在至少某種程度上可溶解試劑。所述之反應可在寬範圍之溫度發生及精確的反應溫度係對本發明不關鍵。方便在-78℃至回流之間之溫度範圍進行所述之反應。取決於許多因素,尤其反應溫度及試劑之性質,反應所需之時間亦可廣泛變化。然而,自0.5小時至若干天之時間通常足以生成所述之中間體及化合物。反應順序不限於反應圖中所顯示之順序,然而,取決於起始物質及其各自之反應性可自由改變反應步驟之順序。起始物質係市面上可購得的或可藉由類似於以下給出之方法、藉由描述或實例中引用之參考文獻中描述之方法或藉由此項技術中已知之方法進行製備。 反應圖1a) 鹵化物II
係市面上可購得或可根據此項技術中已知之方法合成。該等鹵化物II
可方便地於(諸如)乙腈、乙醇或DMF之適宜溶劑中與疊氮化鈉反應以提供疊氮化物衍生物III
。替代之較佳條件涉及如DMA、NMP或DMSO,甚至更佳地NMP及DMSO之溶劑之使用。於如NMP及DMSO之極性非質子溶劑中,通常可在比(例如)乙腈中更低溫度,經常在室溫至40℃(此為針對以下之情況,例如BnCl、1-氯-2-(氯甲基)苯或PMB-Cl;此當然取決於鹵化物II
之反應性)進行烷基化及因此提供更佳的程序安全性窗口(注意當然已知有機疊氮化物係潛在危險的及程序安全性總是需要仔細評估)。水之加入可係有利的,由於其增加疊氮化鈉之溶解度及提供更強大的動力學特性,因為其有助於溶解NaN3
硬塊。其可導致最終疊氮化物反應混合物之更佳的過濾性。(例如)當於小通道反應器中以連續模式進行以下環加成時可需反應混合物之過濾。不單離疊氮化物及最好在下一步引入其溶液。此亦避免亦可導致安全性問題之其單離。 b)可藉由在(諸如)甲醇鈉或乙醇鈉之適宜鹼之存在下,於(諸如)甲醇、乙醇或DMF之適宜溶劑中,疊氮化物衍生物III
與2-氰基乙醯胺之[3+2]環加成製備三唑衍生物IV
。替代之較佳條件涉及於氫氧化鈉之存在下於如NMP或DMSO之溶劑中,該疊氮化物與2-氰基乙醯胺反應。該分批法通常在室溫至50℃,較佳地在室溫與40℃之間進行(注意,程序安全性總是需要仔細評估)。該環加成製程亦可修正為連續模式 (相關文獻實例,參見Org. Process Res. Dev.
,2009
, 13 (6),第1401頁至1406頁)及於此情況中可增加反應溫度在50℃以上,例如(但不限於)在50℃與90℃之間,較佳地在60℃與70℃之間。 c)可藉由在(諸如)DIEA、DMAP、吡啶等等之鹼之存在下,IV
與醯基-鹵之醯化作用獲得三唑衍生物V
。觀察到雙醯化作用及腈副產物之形成。當(例如)於作為溶劑之吡啶中處理時此可係重要的。然而,當使用DMA或NMP,較佳地DMA作為溶劑替代吡啶時,此等可最小化。較佳條件涉及在50至100℃下,較佳地在75至85℃之間,1.0至2當量,較佳地1.0至1.5當量,較佳地約1.5當量之吡啶及特戊醯氯之使用。該等高沸極性溶劑亦允許壓縮以下環化步驟,其極大地簡化製程。 d)可藉由在(諸如)KHCO3
、Na2
CO3
之鹼及有或無(諸如)甲醇、乙醇、二噁烷及甲苯之溶劑之水之存在下,三唑衍生物V
之分子內環化製備三唑并嘧啶衍生物VI
。替代之較佳條件涉及作為溶劑之DMA或NMP,較佳地DMA之使用。可在KHCO3
之存在下在130至170℃,較佳地在140與160℃之間進行該反應。化合物VI
可作為互變異構體或互變異構體之混合物存在,例如:視情況可在(諸如)K2
CO3
之鹼之存在下,於(諸如)DMF之溶劑中,優先地在接近溶劑之沸點之溫度下,胺基醯胺IV
與腈R4
-CN反應以直接獲得嘧啶酮VI
。 e)可藉由在(諸如)N,N
-二乙基苯胺、二甲吡啶或吡啶之適宜鹼之存在下,VI
與(諸如)POCl3
、SOCl2
或(COCl)2
之氯化試劑之反應獲得氯化物VII
。替代之較佳條件涉及作為氯化試劑之維爾斯邁爾(Vilsmeier)試劑之使用。其亦可藉由草醯氯與DMF之反應原位生成。可於(例如)乙腈、DCM或AcOEt中,較佳地於DCM中進行氯化。該等條件允許溫和的反應溫度及(例如)避免處理中過量POCl3
之中止。可於下一步引入粗產物。 f)在(諸如)三乙胺、DIEA或DBU之適宜鹼之存在下,於(諸如)乙腈、甲醇、甲苯或DMF之適宜溶劑中氯化物VII
可方便地與胺親核試劑反應以生成三唑并-嘧啶衍生物I
。 該等衍生物可為最終化合物,然而較佳地當R1
-CH2
=經取代之苄基(諸如對甲氧苄基)時,該等基團可由TFA、CAN裂解、氫化及類似以獲得衍生物I
(R1
-CH2
=H)。R1
-CH2
=苄基代表適宜替代保護基。其避免PMB-Cl(用於製備對應之疊氮化物中間體III
)的使用,已知其具有一些熱穩定性問題(參見(例如)Organic Process Research & Development 2005
, 9, 1009-1012)及可變之品質,端視供應商而定。可在標準氫解條件下,亦(例如)於酸之存在下使苄基裂解。當使用HCl時,可可能作為鹽單離衍生物I
R1
-CH2
=H)。 在(諸如)DIEA、DBU、K2
CO3
或Cs2
CO3
之適宜鹼之存在下,於(諸如)DMF、二噁烷或甲苯之溶劑中,三唑衍生物I
(R1
-CH2
=H)可方便地與鹵化物(或(諸如)甲磺酸鹽、九氟丁磺酸鹽或甲苯磺酸鹽之磺酸鹽)反應或在光延(Mitsunobu)反應條件下使用適宜重氮基二羧酸酯(DEAD、DIAD等等)及(諸如)PBu3
或PPh3
之膦,於(諸如)THF、DCM、甲苯之適宜溶劑中與醇反應以提供最終的三唑并-嘧啶衍生物I
。 若起始物質、式II
之化合物、用於步驟c)之醯化試劑或用於步驟f)之胺之一包含一個或多個在一個或多個反應步驟之反應條件下不穩定的或具反應性的官能基,則可在關鍵步驟之前應用此項技術中熟知之方法引入適宜保護基(P)(如(例如)T.W. Greene等人,Protective Groups in Organic Chemistry,John Wiley and Sons Inc. New York1999
,第3版中所述)。可在合成之後期使用此項技術中已知之標準方法移除該等保護基。 若一種或多種式II
至VII
之化合物、用於步驟d)之醯化試劑或用於步驟f)之胺包含對掌性中心,則可獲得作為非對映異構體或對映異構體之混合物之式I
之三唑并嘧啶,該等混合物可藉由此項技術中熟知之方法(例如(對掌性)HPLC或結晶化)分離。可(例如)經由非對映異構體之鹽,藉由結晶化或藉由特定層析方法利用對掌性吸附劑或對掌性溶離劑分離對映體來分離外消旋化合物至其對映體。 本發明亦係關於一種用於製備式(I)之化合物之方法,其包括於式(B)化合物及鹼之存在下,式(A)之化合物之反應, (A) (B)
其中R1
至R4
及n係如以上所定義。 於本發明之方法中,鹼為(例如)三乙胺、DIEA或DBU。 於本發明之方法中,可使用可選自(例如)乙腈、甲醇、甲苯及DMF之溶劑。 因此本發明亦係關於當根據本發明之方法製備時的式(I)之化合物。 本發明之另一實施例提供包含本發明之化合物及治療惰性載劑、稀釋液或賦形劑之醫藥組合物或藥劑,以及使用本發明之化合物製備此等組合物及藥劑之方法。於一個實例中,可藉由在環境溫度下在適宜pH下及在所需純度下與生理學上可接受之載劑(即,在採用蓋倫投藥形式(galenical administration form)之劑量及濃度下對接受者無毒的載劑)混合調配式(I)之化合物。雖然調配物之pH主要取決於化合物之特定用途及濃度,但較佳地自約3至約8不等。於一個實例中,於乙酸鹽緩衝液中在pH 5調配式(I)之化合物。於另一實施例中,式(I)之化合物係無菌的。該化合物(例如)作為固體或非晶型組合物,作為凍乾調配物或作為水溶液可經貯存。 組合物係依符合良好醫療實務的方式調配、定劑量及投與。於上下文中需要考慮之因素包括所治療之特定疾病、所治療之特定哺乳動物、個別患者之臨床病狀、疾病之原因、藥劑之遞送位置、給藥之方法、給藥計畫及其他醫師已知之因素。 本發明之化合物可依任何適宜方式給藥,其包括口服、局部(包括口腔及舌下)、直腸、陰道、穿皮、非經腸、皮下、腹膜內、肺內、皮內、鞘內及硬膜外及鼻內及若所需進行局部治療之病竈內投與。非經腸輸注包括肌肉內、靜脈內、動脈內、腹膜內或皮下給藥。 本發明之化合物可以(例如)錠劑、粉劑、膠囊、溶液、分散液、懸浮液、糖漿、噴霧、栓劑、凝膠、乳劑、貼劑等之任何方便的給藥形式給藥。該等組合物可包含醫藥製劑中習知之組分,(例如)稀釋劑、載劑、pH調節劑、甜味劑、增積劑及其他活性劑。 藉由將本發明之化合物與載體或賦形劑混合製備典型之調配物。適宜載劑及賦形劑為熟習此項技術者所熟知及於(例如) Ansel, Howard C.等人,Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004;Gennaro, Alfonso R. 等人,Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000;及Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005中詳細描述。該調配物亦可包含一種或多種緩衝劑、穩定劑、表面活性劑、潤濕劑、潤滑劑、乳化劑、懸浮劑、防腐劑、抗氧化劑、蔽光劑、助流劑、加工助劑、著色劑、甜味劑、芳香劑、調味劑、稀釋劑及其他已知添加劑以提供藥劑(即本發明之化合物或其醫藥組合物)之優雅呈現或協助製造醫藥產品(即藥劑)。 因此本發明亦係關於: 用作治療活性物質之式(I)之化合物; 包含式(I)之化合物及治療惰性載劑之醫藥組合物; 式(I)之化合物之用途,其用於製備用於治療或預防疼痛、神經痛、動脈粥樣硬化、年齡相關之黃斑變性、糖尿病性視網膜病、青光眼、糖尿病、炎症、炎性腸病、局部缺血再灌注損傷、急性肝衰竭、肝纖維化、肺纖維化、腎纖維化、全身性纖維化、急性同種異體移植排斥、慢性同種異體移植腎病、糖尿病性腎病、腎小球性腎病、心肌病、心臟衰竭、心肌缺血/梗塞、全身性硬化病、燙傷、燒傷、肥厚性瘢痕、瘢痕瘤、齦炎發熱、肝硬化或腫瘤、骨質調節、神經退化、中風、短暫性腦缺血發作、葡萄膜炎、哮喘、骨質疏鬆症、精神性疾病、精神病、腫瘤學、腦炎、瘧疾、過敏症、免疫學病症、關節炎、胃腸疾病、類風濕性關節炎或過敏症之藥劑; 式(I)之化合物,其用於治療或預防疼痛、神經痛、動脈粥樣硬化、年齡相關之黃斑變性、糖尿病性視網膜病、青光眼、糖尿病、炎症、炎性腸病、局部缺血再灌注損傷、急性肝衰竭、肝纖維化、肺纖維化、腎纖維化、全身性纖維化、急性同種異體移植排斥、慢性同種異體移植腎病、糖尿病性腎病、腎小球性腎病、心肌病、心臟衰竭、心肌缺血/梗塞、全身性硬化病、燙傷、燒傷、肥厚性瘢痕、瘢痕瘤、齦炎發熱、肝硬化或腫瘤、骨質調節、神經退化、中風、短暫性腦缺血發作、葡萄膜炎、哮喘、骨質疏鬆症、精神性疾病、精神病、腫瘤學、腦炎、瘧疾、過敏症、免疫學病症、關節炎、胃腸疾病、類風濕性關節炎或過敏症; 一種用於治療或預防疼痛、神經痛、動脈粥樣硬化、年齡相關之黃斑變性、糖尿病性視網膜病、青光眼、糖尿病、炎症、炎性腸病、局部缺血再灌注損傷、急性肝衰竭、肝纖維化、肺纖維化、腎纖維化、全身性纖維化、急性同種異體移植排斥、慢性同種異體移植腎病、糖尿病性腎病、腎小球性腎病、心肌病、心臟衰竭、心肌缺血/梗塞、全身性硬化病、燙傷、燒傷、肥厚性瘢痕、瘢痕瘤、齦炎發熱、肝硬化或腫瘤、骨質調節、神經退化、中風、短暫性腦缺血發作、葡萄膜炎、哮喘、骨質疏鬆症、精神性疾病、精神病、腫瘤學、腦炎、瘧疾、過敏症、免疫學病症、關節炎、胃腸疾病、類風濕性關節炎或過敏症之之方法,該方法包括投與有效量之式(I)之化合物給有此需要之患者;及 式(I)之化合物用於CB2受體之檢測或成像之用途。 現將藉由不具有限制特性之以下實例說明本發明。實例
縮寫 MS=質譜法;CAN=硝酸鈰銨;CAN=化學文摘服務編號;Ac=乙醯基;DIEA=N,N
-二異丙基乙胺;DBU=1,8-二氮雜二環[5.4.0]十一-7-烯;DMF=二甲基甲醯胺;HPLC=LC=高效液相層析;HRMS=高解析度質譜法;MeCN=乙腈;NBS=N
-溴代琥珀醯亞胺;NCS=N
-氯琥珀醯亞胺;NMR資料係以相對於內部四甲基矽烷之百萬分率(d)計及參照來自樣品溶劑(d6
-DMSO,除非另作指明)之氘鎖訊號報告;耦合常數(J)以赫茲計;THF=四氫呋喃;TFA=三氟乙酸;DCM=二氯甲烷。實例 1 2-[[5- 第三丁基 -7-[(3S)-3- 羥基吡咯啶 -1- 基 ] 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯磺醯氟 a) 2-(溴甲基)苯-1-磺醯氟使苯甲磺醯氟(CAS 444-31-5,350 mg,2.01 mmol,1 equiv)、NBS(429 mg,2.41 mmol,1.2 equiv)及AIBN (33 mg,0.20 mmol,0.1 equiv)含於MeCN (2.00 mL)中之混合物回流過夜。移除溶劑並添加甲苯(5 mL)。經矽藻土過濾懸浮液(用另外的甲苯沖洗)並濃縮濾液。在矽石上之急驟層析(1.5% EtOAc含於己烷中)得到呈無色固體之2-(溴甲基)苯-1-磺醯氟(407 mg,1.6 mmol,80%產率)。HRMS (EI+) 251.9251(M+
)。 b) 2-[[5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟 在室溫下,將(3S)-1-(5-第三丁基-3H-三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇(CAS 1433946-74-7,50 mg,0.19 mmol,1.0 equiv)與2-(溴甲基)苯-1-磺醯氟(53 mg,0.21 mmol,1.1 equiv)溶解於DMF(1.0 mL)中。接著添加NEt3
(40 µl,0.29 mmol,1.5 equiv)並攪拌反應混合物1小時。將該混合物用EtOAc (20 mL)稀釋,用5%LiCl水溶液 (2 x 2 mL)及鹽水(1 x 5 mL)洗滌,經MgSO4
乾燥,過濾並濃縮。在矽石上之急驟層析(EtOAc/己烷/AcOH 5:5:1)得到呈無色油之2-[[5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟(23 mg,0.053 mmol,28%產率)。HRMS (ESI+)435.1607(M+H+
)。實例 2 (2-{[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 )-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 } 苯基 ) 甲磺醯氟 a)鄰甲苯基甲磺醯氟將1-(氯甲基)-2-甲苯(CAS 552-45-4,3.35 g,23.8 mmol,1.00 equiv)及硫脲(1.81 g,23.8 mmol,1.00 equiv)與EtOH(24 mL)合併並回流1小時。移除溶劑以留下無色固體。添加MeCN (34.3 mL)及HCl水溶液(2M,6.9 mL)並將其攪拌直至大多數固體溶解。接著以溫度不升至23℃以上(內部溫度,用冰浴冷卻)之速率分部分添加NCS (12.7 g,95.1 mmol,4 equiv)。完成添加後,移除該冰浴並攪拌黃色混合物30分鐘。接著將其倒入另外含有水(100 mL)之添加漏斗,藉助乙醚定量轉移。接著用乙醚(3 x 50 mL)萃取水相。將合併之有機物用飽和NaHCO3
水溶液(30 mL)及鹽水(30 mL)洗滌,經MgSO4
乾燥,過濾並濃縮得到5.84 g粗物質,將粗物質溶解於丙酮:水(100 mL)之3:1混合物。添加氟化鉀(2.77 g,47.6 mmol,2 equiv)。攪拌過夜後,將混合物用水(300 mL)稀釋及用乙醚(3x100 mL)萃取。將合併之有機物用飽和NaHCO3
水溶液(30 mL)、水(30 mL)及鹽水(30 mL)洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(5%EtOAc含於己烷)得到呈無色油之鄰甲苯基甲磺醯氟(2.04 g,10.8 mmol,45.5%產率),過夜固化。HRMS (EI+) 188.0303 (M+
)。 b) (2-(溴甲基)苯基)甲磺醯氟將鄰甲苯基甲磺醯氟(188 mg,1.00 mmol,1 equiv)、NBS(196 mg,1.10 mmol,1.1 equiv)及過氧化苯甲醯(32.3 mg,0.10 mmol,0.1 equiv)與CCl4
(5.00 mL)合併並回流3小時。移除溶劑及在矽石上之急驟層析(15% CH2
Cl2
含於己烷)得到呈無色固體之(2-(溴甲基)苯基)甲磺醯氟(213 mg,0.750 mmol,純度94% (6%起始物質),71%產率)。HRMS (EI+) 265.9410 (M+
)。 c) (2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲磺醯氟 類似於2-[[5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟(實例1,步驟b)之合成所述之程序,自5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1438465-59-8,50 mg,0.18 mmol)與(2-(溴甲基)苯基)甲磺醯氟製備標題化合物及單離呈無色油(15 mg,0.032 mmol,18%產率)。HRMS (ESI+) 469.1624 (M+H+
)。實例 3 [2-({5- 第三丁基 -7-[(3S)-3- 羥基吡咯啶 -1- 基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -3- 基 } 甲基 ) 苯基 ] 甲磺醯氟 類似於2-[[5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟(實例1,步驟b)之合成所述之程序,自(3S)-1-(5-第三丁基-3H-三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇(CAS 1433946-74-7,55 mg,0.21 mmol,1.0 equiv)與(2-(溴甲基)苯基)甲磺醯氟製備標題化合物及單離呈無色油(31 mg,0.069 mmol,33%產率)。HRMS (ESI+) 449.1767 (M+H+
)。實例 4 5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 )-3-{[2-( 異硫氰基甲基 ) 苯基 ] 甲基 }-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 a)1-(疊氮甲基)-2-(氯甲基)苯將鄰亞二甲苯基二氯化物(CAS 612-12-4,3.23 g,18.4 mmol,1.00 equiv)溶解於DMSO(18.4 mL)中並添加NaN3
(1.20 g,18.4 mmol,1.00 equiv)。於2小時後,將反應混合物用水(200 mL)稀釋及用EtOAc(3x70 mL)萃取。將有機相用鹽水(2x20 mL)洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之重複急驟層析(2%EtOAc含於己烷)得到呈無色油之1-(疊氮甲基)-2-(氯甲基)苯(520 mg,2.86 mmol,15.5%產率)。1
H NMR(400 MHz, CDCl3
) δ = 7.48-7.32 (m, 4H), 4.68 (s, 2H), 4.53 (s, 2H)。13
C NMR (101 MHz, CDCl3
) δ = 136.0, 134.3, 130.8, 130.2, 129.4, 129.2, 52.1, 43.6。 b) 1-(氯甲基)-2-(異硫氰基甲基)苯在室溫下,將1-(疊氮甲基)-2-(氯甲基)苯(421 mg,2.32 mmol,1.00 equiv)及三苯基膦(669 mg,2.55 mmol,1.10 equiv)溶解於CHCl3
(4.65 mL)中。添加CS2
(1.19 mL,19.7 mmol,8.50 mmol)並將混合物攪拌1小時。該混合物直接接受在矽石上之急驟層析(2%EtOAc含於己烷)以得到呈無色油之1-(氯甲基-2-(異硫氰基甲基)苯(114 mg,0.577 mmol,24.9%產率)。HRMS (EI+) 197.0054(M+
)。 c) 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶 類似於2-[[5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟(實例1,步驟b)之合成所述之程序,自5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1438465-59-8,56 mg,0.20 mmol)與1-(氯甲基)-2-(異硫氰基甲基)苯製備標題化合物及單離呈無色油(37 mg,0.083 mmol,42%產率)。HRMS (ESI+) 444.1772(M+H+
)。實例 5 (3S)-1-(5- 第三丁基 -3-{[2-( 異硫氰基甲基 ) 苯基 ] 甲基 }-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -7- 基 ) 吡咯啶 -3- 醇 類似於2-[[5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟(實例1,步驟b)之合成所述之程序,自(3S)-1-(5-第三丁基-3H-三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇(CAS 1433946-74-7,57 mg,0.22 mmol,1.0 equiv)與1-(氯甲基)-2-(異硫氰基甲基)苯製備標題化合物及單離呈無色油(45 mg,0.106 mmol,49%產率)。HRMS (ESI+) 424.1916(M+H+
)。實例 6 5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 )-3-[(2- 異硫氰基苯基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 類似於2-[[5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟(實例1,步驟b)之合成所述之程序,自5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1438465-59-8,45 mg,0.16 mmol)與1-溴甲基-2-異硫氰基苯(CAS 108288-40-0)製備標題化合物及單離呈無色油(20 mg,0.047 mmol,29%產率)。HRMS (ESI+) 430.1621 (M+H+
)。實例 7 2-{[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 )-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 } 苯 -1- 磺醯氟 類似於2-[[5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟(實例1,步驟b)之合成所述之程序,自5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1438465-59-8,60 mg,0.21 mmol)與2-(溴甲基)苯-1-磺醯氟製備標題化合物及單離呈無色油(33 mg,0.072 mmol,34%產率)。HRMS (ESI+) 455.1470 (M+H+
)。實例 8 1-{5- 第三丁基 -3-[(2- 氯苯基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -7- 基 } 吡咯啶 -3- 硫醇 a)甲磺酸1-(5-(第三丁基)-3-(2-氯苯基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯將1-[5-t第三丁基-3-(2-氯-苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基]-吡咯啶-3-醇(CAS 1433362-08-3,154 mg,0.398 mmol,1.00 equiv)及NEt3
(111 µL,0.796 mmol,2.00 equiv)溶解於CH2
Cl2
(1.80 mL)中並冷卻至0℃。接著作為含於CH2
Cl2
(0.40 mL)中之溶液添加MsCl (62 µL,0.80 mmol,2.0 equiv)。於40分鐘後,將反應混合物用水稀釋及用CH2
Cl2
萃取。濃縮合併之有機物及使殘餘物接受在矽石上之急驟層析(5%EtOAc含於CH2
Cl2
)以得到呈無色油之甲磺酸1-(5-(第三丁基)-3-(2-氯苯基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(170 mg,0.366 mmol,92%產率)。HRMS (ESI+) 465.1469(M+H+
)。 b) 硫代乙酸S-(1-(5-(第三丁基)-3-(2-氯苯基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯將甲磺酸1-(5-(第三丁基)-3-(2-氯苯基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(361 mg,0.776 mmol,1.00 equiv)溶解於DMF(7.76 mL)中,添加硫代乙酸鉀(887 mg,7.76 mmol,10.0 equiv)並在50℃下將混合物攪拌2小時。於冷卻至室溫後,將混合物用水稀釋及用EtOAc萃取。將有機物用稀NaHCO3
水溶液及鹽水洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(梯度10%至20%EtOAc含於己烷)得到呈無色固體之硫代乙酸S-(1-(5-(第三丁基)-3-(2-氯苯基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯(345 mg,0.735 mmol,95%產率)。HRMS (ESI+) 445.1579 (M+H+
)。 c) 1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇 將硫代乙酸S-(1-(5-(第三丁基)-3-(2-氯苯基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯(109 mg,0.245 mmol,1.00 equiv)溶解於MeOH與THF之1:1混合物(2.40 mL)。添加K2
CO3
(203 mg,1.47 mmol,6 equiv)並將混合物攪拌15分鐘。將反應混合物用水(50 mL)稀釋及用EtOAc (3 x 20 mL)萃取。將有機物用鹽水洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(CH2
Cl2
:己烷:MeOH 50:50:1)得到呈無色油之1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇(86 mg,0.21 mmol,87%產率)。HRMS (ESI+) 403.1468 (M+H+
)。實例 9 1-{5- 第三丁基 -3-[(2- 氯苯基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -7- 基 } 氮雜環丁烷 -3- 硫醇 在環境溫度下,將5-(第三丁基)-7-氯-3-(2-氯苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1433362-85-6,20 mg,59.5 µmol)、氮雜環丁烷-3-硫醇鹽酸鹽(CAS 179337-60-1,11.2 mg,89.2 µmol)及DIPEA (23.1 mg, 30.5 µL,178 µmol)含於乙腈(3 mL)中之懸浮液攪拌18小時。在減壓下移除溶劑及藉由TLC(矽膠,2.0 mm,3:1庚烷:EtOAc)純化殘餘物以得到呈無色半固態油之標題化合物(11 mg,48%)。HRMS (ESI+) 389.1297 (M+H+
)。實例 10 (3S)-1-{5- 第三丁基 -3-[(4- 甲基 -1,2,5- 噁二唑 -3- 基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -7- 基 } 吡咯啶 -3- 硫醇或對映異構體 a) 3-((5-(第三丁基)-7-氯-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)-4-甲基1,2,5-噁二唑將5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7(4H)-酮(CAS 1919022-49-3,235 mg,0.812 mmol,1.00 equiv)與一滴DMF溶解於CH2
Cl2
(2.71 mL)中。添加草醯氯(80 µL,0.89 mmol,1.1 equiv)並將反應混合物在室溫下攪拌過夜。添加矽藻土及移除溶劑。在矽石上之急驟層析(0.5% MeOH含於CH2
Cl2
)得到呈無色固體之3-((5-(第三丁基)-7-氯-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)-4-甲基1,2,5-噁二唑(230 mg,0.757 mmol,92%產率)。HRMS (MALDI+) 308.1021 (M+
)。 b) 甲磺酸吡咯啶-3-基酯鹽酸鹽將3-甲磺醯基氧基-吡咯啶-1-甲酸第三丁酯(CAS 141699-57-2,768 mg,2.89 mmol,1.00 equiv)溶解於Et2
O(8.7 mL)中並添加HCl (4M含於二噁烷中,8.68 mL,17.4 mmol,6 equiv)。將混合物攪拌過夜,濃縮之及無需進一步純化使用殘餘物。 c) 甲磺酸1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯在室溫下,將3-((5-(第三丁基)-7-氯-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)-4-甲基-1,2,5-噁二唑(300 mg,0.98 mmol,1.00 equiv)溶解於CH2
Cl2
(4.87 mL)中並添加甲磺酸吡咯啶-3-基酯鹽酸鹽(216 mg,1.07 mmol,1.10 equiv)。接著添加NEt3
(272 µL,1.95 mmol,2.00 equiv)並將混合物攪拌30分鐘。添加矽藻土及蒸發溶劑。在矽石上之急驟層析(50% EtOAc含於己烷)得到呈無色油之甲磺酸1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(426 mg,0.89 mmol,91%產率)。HRMS (ESI+) 437.1715 (M+H+
)。 d) 硫代乙酸S-(1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯將甲磺酸1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(147 mg,0.337 mmol,1.0 equiv)及硫代乙酸鉀(385 mg,3.37 mmol,10.0 equiv)與DMF (1.8 mL)合併並加熱至50℃持續2小時。將反應混合物冷卻至室溫及用EtOAc (50 mL)稀釋。將有機相用水(10 mL)、5% LiCl水溶液(10 mL)及鹽水(10 mL)洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(15% EtOAc含於己烷)提供硫代乙酸S-(1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯(107 mg,0.257 mmol,76%產率)。HRMS (ESI+) 417.1813 (M+H+
)。 e)硫代乙酸S-[(3S)-1-[5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]三唑并[4,5-d]嘧啶-7-基]吡咯啶-3-基]酯藉由對掌性HPLC使外消旋硫代乙酸S-(1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯(107 mg,0.257 mmol)接受分離以產生標題化合物(25 mg,0.06 mmol,23%)。 f) (3S)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇 在環境溫度下,將硫代乙酸S-[(3S)-1-[5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]三唑并[4,5-d]嘧啶-7-基]吡咯啶-3-基]酯(25 mg,0.06 mmol)及K2
CO3
(45.6 mg,330 µmol)含於THF(3 mL)、水(1 mL)及甲醇(1 mL)中之混合物攪拌72小時。將反應混合物倒入水中(30 mL)並用EtOAc (2 x 30 mL)萃取。將合併之萃取物用水/鹽水(1:1)洗滌,經Na2
SO4
乾燥及在減壓下濃縮。藉由製備型TLC(矽膠,1.0 mm,1:1庚烷/EtOAc)純化粗產物以產生呈無色固體之標題化合物(12 mg,52%產率)。MS(ESI): m/z = 374.1[M]+
。實例 11 (3R)-1-{5- 第三丁基 -3-[(4- 甲基 -1,2,5- 噁二唑 -3- 基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -7- 基 } 吡咯啶 -3- 硫醇或對映異構體 a) 硫代乙酸S-[(3R)-1-[5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]三唑并[4,5-d]嘧啶-7-基]吡咯啶-3-基]酯藉由對掌性HPLC使外消旋硫代乙酸S-(1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯(107 mg,0.257 mmol)接受分離以產生標題化合物(33 mg,0.08 mmol,31%)。 b) (3R)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇 類似於實例10(步驟f)中所述之程序,將硫代乙酸S-[(3R)-1-[5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]三唑并[4,5-d]嘧啶-7-基]吡咯啶-3-基]酯水解以獲得呈無色固體之標題化合物(14 mg,61%)。MS(ESI): m/z = 374.1[M]+ 實例 12 (3S)-1-{5- 第三丁基 -3-[(2- 氯苯基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -7- 基 } 吡咯啶 -3- 硫醇或對映異構體 類似於(3S)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇(實例10,步驟a、c至f)之合成所述之程序,自5-第三丁基-7-氯-3-(2-氯苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1433362-85-6)製備呈無色固體之標題化合物(11 mg,60%)。1
H NMR (300 MHz, CDCl3) δ = 1.20-1.32(m, 1 H) 1.36 (s, 9 H) 2.17-2.50 (m, 2 H) 3.87-4.20 (m, 2 H) 4.25-4.61 (m, 2 H) 5.86 (s, 2 H) 7.14-7.25 (m, 3 H) 7.38-7.41 (m, 1 H)。實例 13 (3R)-1-{5- 第三丁基 -3-[(2- 氯苯基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 -7- 基 } 吡咯啶 -3- 硫醇或對映異構體 類似於(3S)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇(實例10,步驟a、c至f)之合成所述之程序,自5-第三丁基-7-氯-3-(2-氯苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1433362-85-6)製備呈無色固體之標題化合物(12 mg,60%)。1
H NMR (300 MHz, CDCl3
) δ = 1.21-1.32 (m, 1 H) 1.36 (s, 9 H) 2.19-2.39 (m, 2 H) 3.87-4.22 (m, 2 H) 4.27-4.61 (m, 2 H) 5.86 (s, 2 H) 7.13-7.25 (m, 3 H) 7.38-7.40 (m, 1 H)。實例 14 7-(3- 疊氮基吡咯啶 -1- 基 )-5- 第三丁基 -3-[(4- 甲基 -1,2,5- 噁二唑 -3- 基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 將甲磺酸1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(194 mg,0.444 mmol,1.00 equiv)溶解於DMF(3.70 mL)中並添加NaN3
(144 mg,2.22 mmol,5 equiv)。將反應混合物在90℃下攪拌1小時。於冷卻至室溫後,將混合物用水稀釋及用EtOAc萃取。將合併之有機物用鹽水洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(20%EtOAc含於己烷)得到呈無色油之7-(3-疊氮基吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(153 mg,0.399 mmol,90%產率)。HRMS (ESI+) 384.2005 (M+H+
)。實例 15 5- 第三丁基 -3-[(2- 氯苯基 ) 甲基 ]-7-(3- 異硫氰基吡咯啶 -1- 基 )-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 a) 1-(5-(第三丁基)-3-(2-氯苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-胺將7-(3-疊氮基吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(32 mg,0.078 mmol,1.0 equiv)、水(28 µL,1.6 mmol,20 equiv)及PPh3
(41 mg,0.16 mmol,2.0 equiv)與THF(710 µL)合併並在50℃攪拌1.5小時。添加矽藻土及移除溶劑。在矽石上之急驟層析(10% MeOH含於CH2
Cl2
)得到呈無色固體之1-(5-(第三丁基)-3-(2-氯苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-胺(21 mg,0.054 mmol,70%產率)。HRMS (ESI+) 386.1857 (M+H+
)。 b) 5-第三丁基-3-[(2-氯苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶 將1-(5-(第三丁基)-3-(2-氯苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-胺(12 mg,0.031 mmol,1.0 equiv)與N,N'-硫代羰基二咪唑(11 mg,0.062 mmol,2.0 equiv)於THF(155 µL)中合併並攪拌過夜。添加矽藻土及移除溶劑。在矽石上之急驟層析得到呈無色油之5-第三丁基-3-[(2-氯苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(6.5 mg,0.015 mmol,49%產率)。1
H NMR (300 MHz, 氯仿-d) δ = 7.43-7.38 (m, 1H), 7.27-7.17 (m, 3H), 5.87 (s, 2H), 4.64-4.47 (m, 2H), 4.40-4.27 (m, 1H), 4.17-4.04 (m, 1H), 4.02-3.92 (m, 1H), 2.55-2.27 (m, 2H), 1.37 (s, 9H)。實例 16 5- 第三丁基 -7-(3- 異硫氰基吡咯啶 -1- 基 )-3-[(4- 甲基 -1,2,5- 噁二唑 -3- 基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 將7-(3-疊氮基吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(50 mg,0.13 mmol,1.0 equiv)、PPh3
(41 mg,0.16 mmol,1.2 equiv)溶解於THF(650 µL)中並添加CS2
(79 µL,1.3 mmol,10 equiv)。將反應混合物在室溫下攪拌過夜。添加矽藻土及移除溶劑。在矽石上之急驟層析(20%EtOAc含於己烷)得到呈無色油之5-第三丁基-7-(3-異硫氰基吡咯啶-1-基)-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(33 mg,0.083 mmol,63%產率)。HRMS (ESI+) 400.1665 (M+H+
)。實例 17 7-(3- 疊氮基吡咯啶 -1- 基 )-5- 第三丁基 -3-[(2- 氯苯基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 類似於7-(3-疊氮基吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(實例14)之合成所述之程序,自甲磺酸1-(5-(第三丁基)-3-(2-氯苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯製備標題化合物及單離呈無色油。HRMS (ESI+) 412.1763 (M+H+
)。實例 18 5-[ 二氟 ( 苯基 ) 甲基 ]-7-[3-( 甲基二硫基 ) 吡咯啶 -1- 基 ]-3-[(4- 甲基 -1,2,5- 噁二唑 -3- 基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 a) 5-胺基-1-((4-甲基-1,2,5-噁二唑-3-基)甲基)-1H-1,2,3-三唑-4-甲醯胺將5-胺基-1-(2-氯苄基)-1H-1,2,3-三唑-4-甲醯胺(CAS 93444-91-8,2.01 g,15.2 mmol,1.0 equiv)及DIPEA(0.27 mL,1.52 mmol,0.1 equiv)溶解於DMSO (9.7 mL)中並分部分添加NaN3
(1.04 g,15.9 mmol,1.05 equiv)。將反應混合物在室溫下攪拌過夜。於第二反應容器中,先將氰基乙醯胺(1.91 g,22.8 mmol,1.5 equiv)溶解於DMSO (7.8 mL)及水(1.2 mL)中。接著緩慢添加32% NaOH水溶液(1.4 mL,15.2 mL,1.0 equiv) (放熱)並攪拌混合物15分鐘。緩慢添加先前製備之有機疊氮化物溶液(放熱)並將反應混合物在室溫下攪拌過夜。緩慢添加水(20 mL)(放熱)。將所得懸浮液冷卻至0℃並攪拌1小時。過濾(用水洗滌,2x5 mL)及乾燥,得到呈米色固體之5-胺基-1-((4-甲基-1,2,5-噁二唑-3-基)甲基)-1H-1,2,3-三唑-4-甲醯胺(2.0 g,9.0 mmol,59%產率)。 b) 5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7(4H)-酮將5-胺基-1-((4-甲基-1,2,5-噁二唑-3-基)甲基)-1H-1,2,3-三唑-4-甲醯胺(1.50 g,6.72 mmol,1.00 equiv)、2,2-二氟-2-苯乙腈(1.60 g,10.5 mmol,1.56 equiv)及K2
CO3
(4.64 g,33.6 mmol,5.00 equiv)與DMF (19.2 ml)合併並加熱至90℃過夜。將反應混合物冷卻至室溫並倒入冰水中。添加HCl水溶液(1M)直至pH = 3並將混合物用EtOAc(3x100 mL)萃取。將合併之有機物用5% LiCl水溶液及鹽水洗滌,經MgSO4
乾燥,過濾及濃縮以留下棕色油。用2-PrOH將殘餘物研磨及過濾得到淡黃色固體(1.45 g)。將濾液濃縮及在矽石上層析(CH2
Cl2
:丙酮 9:1 + 1% MeOH)。將含有產物之溶離份合併、濃縮及再次用2-PrOH研磨殘餘物以得到另一份5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7(4H)-酮(合併為1.72 g,4.79 mmol,71%產率)。HRMS (ESI+) 360.1015 (M+H+
)。 c)3-((7-氯-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)-4-甲基-1,2,5-噁二唑將5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7(4H)-酮(112 mg,0.237 mmol,1.00 equiv)溶解於CH2
Cl2
(790 µL)中並添加一滴DMF。逐滴添加草醯氯(42 µL,0.474 mmol,2.00 equiv)及將混合物加熱至回流持續1.5小時。將反應混合物冷卻至室溫並用EtOAc (30 mL)稀釋。將有機相用水及鹽水洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(20% EtOAc含於己烷)得到呈無色油之3-((7-氯-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)-4-甲基-1,2,5-噁二唑(80 mg,0.21 mmol,89%產率)。HRMS (ESI+) 378.0677 (M+H+
)。 d)甲磺酸1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯將3-((7-氯-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)-4-甲基-1,2,5-噁二唑(151 mg,0.401 mmol,1.00 equiv)與甲磺酸吡咯啶-3-基酯鹽酸鹽(97 mg,0.48 mmol,1.2 equiv)及CH2
Cl2
(1.34 mL)合併。添加NEt3
(112 µL,0.802 mmol,2.00 equiv)並將混合物攪拌30分鐘。添加矽藻土及移除溶劑。在矽石上之急驟層析(50%EtOAc含於己烷)得到甲磺酸1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(165 mg,0.326 mmol,81%產率)。HRMS (ESI+) 507.1374 (M+H+
)。 e) 硫代乙酸S-(1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯類似於硫代乙酸S-(1-(5-(第三丁基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯(實例10,步驟d)之合成所述之程序,自甲磺酸1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(92 mg,0.182 mmol)合成標題化合物及單離呈微黃色蠟 (80 mg,0.164 mmol,91%產率)。1
H NMR (300 MHz,氯仿-d) δ = 7.70-7.62 (m, 2H), 7.42-7.35 (m, 3H), 5.90 (s, 2H), 4.61 (dd, J=12.2, 6.2, 0.5H), 4.34-4.08 (m, 3H), 3.89 (td, J=7.0, 2.9, 1H), 3.76 (dd, J=12.5, 4.7, 0.5H), 2.63-2.39 (m, 1H), 2.36 (s, 1.5H), 2.34 (s, 1.5H), 2.34 (s, 3H), 2.24-2.01 (m, 1H),旋轉異構體之混合物。 f) 1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-硫醇將硫代乙酸S-(1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基)酯(35 mg,0.072 mmol,1.0 equiv)溶解於THF (700 µL)中並冷卻至0℃。添加NaOMe (1M含於MeOH中,94 µL,0.94 mmol,1.3 equiv)並將混合物攪拌1小時。添加飽和NH4
Cl水溶液及用EtOAc萃取混合物。將合併之有機物經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(25%EtOAc含於己烷)得到呈無色固體之1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-硫醇(22 mg,0.049 mmol,69%產率)。HRMS (ESI+) 445.1371 (M+H+
)。 g) 5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶 將甲磺酸甲酯(160 μl,0.056 mmol,1.3 equiv,於EtOH中1:30稀釋)添加至1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-硫醇(19 mg,0.043 mmol,1.0 equiv)含於NaH2
PO4
緩衝液(0.5M,260 μL)及EtOH(450 μL)之溶液。將混合物攪拌12小時。添加另外的甲磺酸甲酯(40 μl,0.011 mmol,0.3 equiv)。將混合物攪拌2小時。添加EtOAc (100 mL)。將混合物用水及鹽水洗滌,經MgSO4
乾燥及濃縮。在矽石上之急驟層析(20% EtOAc含於己烷)得到呈無色油之5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(14 mg,0.029 mmol,67%產率)。HRMS (ESI+) 491.1245 (M+H+
)。實例 19 3-[(2- 氯苯基 ) 甲基 ]-5-[ 二氟 ( 苯基 ) 甲基 ]-7-[3-( 甲基二硫基 ) 吡咯啶 -1- 基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 類似於5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(實例18,步驟b至g)之合成所述之程序,自5-胺基-1-(2-氯苄基)-1H-1,2,3-三唑-4-甲醯胺(CAS 93444-91-8)製備標題化合物及單離呈無色油。HRMS (ESI+) 519.0995 (M+H+
)。實例 20 7-(3- 疊氮基吡咯啶 -1- 基 )-5-[ 二氟 ( 苯基 ) 甲基 ]-3-[(4- 甲基 -1,2,5- 噁二唑 -3- 基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 類似於7-(3-疊氮基吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(實例14)之合成所述之程序,自甲磺酸1-(5-(二氟(苯基)甲基)-3-((4-甲基-1,2,5-噁二唑-3-基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(66 mg,0.13 mmol,1.0 equiv)製備標題化合物及單離呈無色固體(54 mg,0.12 mmol,91%產率)。HRMS (ESI+) 454.1661 (M+H+
)。實例 21 7-(3- 疊氮基吡咯啶 -1- 基 )-3-[(2- 氯苯基 ) 甲基 ]-5-[ 二氟 ( 苯基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 類似於7-(3-疊氮基吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(實例14)之合成所述之程序,自甲磺酸1-(3-(2-氯苯基)-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-基酯(64 mg,0.12 mmol,1.0 equiv)製備標題化合物及單離呈無色固體(47 mg,0.098 mmol,82%產率)。HRMS (ESI+) 482.1412 (M+H+
)。實例 22 3-[(2- 氯苯基 ) 甲基 ]-5-[ 二氟 ( 苯基 ) 甲基 ]-7-(3- 異硫氰基吡咯啶 -1- 基 )-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 將7-(3-疊氮基吡咯啶-1-基)-3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(31 mg,0.064 mmol,1.0 equiv)及CS2
(39 µL,0.64 mmol,10 equiv)溶解於THF(322 µL)中並添加PPh3
(20 mg,0.77 mmol,1.2 equiv)。將反應混合物在室溫下攪拌過夜。添加矽藻土及移除溶劑。在矽石上之急驟層析(25%EtOAc含於己烷)得到呈無色油之3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(16 mg,0.032 mmol,50%產率)。HRMS (ESI+) 498.1069 (M+H+
)。實例 23 5-[ 二氟 ( 苯基 ) 甲基 ]-7-(3- 異硫氰基吡咯啶 -1- 基 )-3-[(4- 甲基 -1,2,5- 噁二唑 -3- 基 ) 甲基 ]-3H-[1,2,3] 三唑并 [4,5-d] 嘧啶 類似於針對3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(實例22)之合成所述之程序,自7-(3-疊氮基吡咯啶-1-基)-5-[二氟(苯基)甲基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶(39 mg,0.086 mmol,1.0 equiv)製備標題化合物及單離呈無色油(18 mg,0.038 mmol,45%產率)。HRMS (ESI+) 470.1314 (M+H+
)。實例 24 2-[[5-[ 二氟 ( 苯基 ) 甲基 ]-7-[(3S)-3- 羥基吡咯啶 -1- 基 ] 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯磺醯氟 a) 5-胺基-1-(2-(苄硫基)苄基)-1H-1,2,3-三唑-4-甲醯胺類似於針對5-胺基-1-(2-乙烯基苄基)-1H-1,2,3-三唑-4-甲醯胺(實例27,步驟a)所述之程序,自鄰苄基巰基苄基氯(CAS 4521-46-4,3.39 g,13.6 mmol,1.00 equiv)、疊氮化鈉(930 mg,14.3 mmol,1.05 equiv)及2-氰基乙醯胺(1.72 g,20.4 mmol,1.50 equiv)製備標題化合物及單離呈無色固體(4.03 g,11.9 mmol,87%)。HRMS (ESI+) 362.1051 (M+Na+
)。 b) 3-(2-(苄硫基)苯基)-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7(4H)-酮將5-胺基-1-(2-(苄硫基)苄基)-1H-1,2,3-三唑-4-甲醯胺(679 mg,2.00 mmol,1.00 equiv)與DMF(4 mL)、2,2-二氟-2-苯乙腈(459 mg,3.00 mmol,1.50 equiv)及K2
CO3
(1.38 g,10.0 mmol,5.00 equiv)合併並加熱至90℃過夜。於冷卻至室溫後,添加水。將沉澱物過濾以產生不純料。藉由在矽石上之急驟層析 (20%丙酮含於甲苯) 進一步純化,得到呈黃色固體之標題化合物(406 mg,0.854 mmol,43%)。HRMS (ESI+) 479.1347 (M+H+
)。 c) 2-((7-氯-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯-1-磺醯氟將3-(2-(苄硫基)苄基)-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7(4H)-酮(150 mg,0.315 mmol,1.00 equiv)與MeCN (6.4 mL)、AcOH(80 µL)及水(0.16 mL)合併並冷卻至-13℃(冰水NaCl,外部溫度)。添加1,3-二氯-5,5-二甲基乙內醯脲(124 mg,0.631 mmol,2.00 equiv)並將混合物在同樣溫度攪拌1.5小時。接著將反應混合物用CH2
Cl2
(100 mL)稀釋,用鹽水洗滌,經MgSO4
乾燥,過濾及濃縮。將粗產物溶解於丙酮(1.0 mL)及水(50 µL)之混合物中。在室溫下添加氟化鉀(92 mg,1.6 mmol,5.0 equiv)並將混合物攪拌過夜。將反應混合物用CH2
Cl2
(100 mL)稀釋,過濾,經MgSO4
乾燥,再次過濾並濃縮。將殘餘物再溶解於CH2
Cl2
(1.6 mL)中。添加DMF (25 µL,0.32 mmol,1.0 equiv),接著添加草醯氯(56 µL,0.63 mmol,2.0 equiv)。將反應混合物在回流下加熱過夜。當TLC分析表明不完全轉化時,添加另一部分草醯氯(56 µL,0.63 mmol,2.0 equiv)並在回流溫度下繼續攪拌2小時。將反應混合物冷卻至室溫,將其用EtOAc(100 mL)稀釋,用半飽和碳酸氫鈉水溶液、5% LiCl水溶液及鹽水洗滌混合物,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(10%至15%至20% EtOAc含於己烷)得到呈黃色油之標題化合物(48 mg,0.11 mmol,經3個步驟33%)。HRMS (ESI+) 454.0352 (M+H+
)。 d) 2-[[5-[二氟(苯基)甲基]-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟將2-((7-氯-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯-1-磺醯氟(20 mg,0.044 mmol,1.0 equiv)與(S)-吡咯啶-3-醇(4.2 mg,0.048 mmol,1.1 equiv)及CH2
Cl2
(0.2 mL)合併。添加三乙胺(9.2 µL,0.066 mmol,1.5 equiv)。於室溫下30分鐘後,將反應混合物用EtOAc(50 mL)稀釋,用5% LiCl水溶液及鹽水(2x)洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(50%EtOAc含於己烷)得到呈無色油之標題化合物(16 mg,0.032 mmol,72%)。HRMS (ESI+) 505.1261 (M+H+
)。實例 25 2-[[2-[[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯基 ] 甲基二硫基 ] 乙醇 a) 硫代苯甲酸S-2-((5-(第三丁基)-7-(3,3-d二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苄基酯(S-2-((5-(tert-Butyl)-7-(3,3-difluoropyrrolidin-1-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)methyl)benzyl benzothioate)將硫代苯甲酸S-2-(碘甲基)苄基酯(160 mg,0.435 mmol,1.05 equiv)及5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1438465-59-8,117 mg,0.414 mmol,1.00 equiv)溶解於DMF (0.8 mL)中。添加NEt3
(87 μL,0.62 mmol,1.5 equiv)並將混合物在室溫下攪拌過夜。用EtOAc(80 mL)稀釋反應混合物,用5% LiCl水溶液(3x10 mL)、鹽水(10 mL)洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(5%至20%EtOAc含於己烷)得到呈無色油之標題化合物(90 mg,0.172 mmol,42%)。HRMS (ESI+) 523.2083 (M+H+
)。 b) 2-[[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]甲基二硫基]乙醇 將硫代苯甲酸S-2-((5-(第三丁基)-7-(3,3-d二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苄基酯(34 mg,0.065 mmol,1.0 equiv)溶解於MeOH (1 mL)及THF (0.8 mL)之混合物中。添加K2
CO3
(45 mg,0.33 mmol,5.0 equiv)並將其攪拌直至TLC表明起始物質之完全轉化。接著將混合物用EtOAc(50 mL)稀釋,用HCl水溶液(0.5M)、水及鹽水(各者10 mL)洗滌,經MgSO4
乾燥,過濾及濃縮。將殘餘物溶解於CH2
Cl2
(0.2 mL)中並在-78℃下添加苯并三唑(7.7 mg,0.065 mmol,1.0 equiv)及1-氯苯并三唑(15 mg,0.095 mmol,1.5 equiv)含於CH2
Cl2
(0.65 mL)中之溶液。將溶液加熱至-20℃並保持該溫度20分鐘。添加巰基乙醇之CH2
Cl2
溶液(0.5M,0.21 mL,0.11 mmol,1.6 equiv)。將溶液在-20℃保持30分鐘。藉由添加硫代硫酸鈉·5H2
O(16 mg,0.065 mmol,1.0 equiv)含於水(0.4 mL)及飽和碳酸氫鈉(0.4 mL)之溶液中止反應並將其在0℃下攪拌10分鐘。添加水(5 mL)及將水相用CH2
Cl2
(3x2 mL)萃取。將合併之有機物經MgSO4
乾燥,過濾並濃縮。在矽石上之急驟層析(5%至25%EtOAc含於己烷)得到經苯并三唑污染之產物。在矽石上之二次急驟層析(7.5%EtOAc含於CH2
Cl2
)得到呈無色油之標題化合物(7.0 mg,0.014 mmol,經兩個步驟22%)。HRMS (ESI+) 495.1808 (M+H+
)。實例 26 2-[[5-[ 二氟 ( 苯基 ) 甲基 ]-7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯磺醯氟 將2-((7-氯-5-(二氟(苯基)甲基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯-1-磺醯氟(10 mg,0.022 mmol,1.0 equiv)及3,3-二氟吡咯啶鹽酸鹽(3.3 mg,0.023 mmol,1.05 equiv)與CH2
Cl2
(0.1 mL)合併。添加三乙胺(7 μL,0.46 mmol,2.1 equiv)。於30分鐘後,使混合物直接接受急驟層析以產生呈無色發泡體之標題化合物(10 mg,0.019 mmol,87%).實例 27 5-[ 二氟 ( 苯基 ) 甲基 ]-7-(3,3- 二氟吡咯啶 -1- 基 )-3-[[2-[2-( 吡啶 -2- 基二硫基 ) 乙基 ] 苯基 ] 甲基 ] 三唑并 [4,5-d] 嘧啶 a) 5-胺基-1-(2-乙烯基苄基)-1H-1,2,3-三唑-4-甲醯胺將疊氮化鈉(0.852 g,13.1 mmol,1.05 eq.)分部分添加至氯甲基苯乙烯(CAS 22570-84-9,1.91 g,12.5 mmol,1.00 equiv)及DIPEA (0.22 mL,1.3 mmol,0.10 equiv)含於DMSO (12.5 mL)中之溶液並在室溫下攪拌1.5小時。接著將懸浮液轉移至含2-氰基乙醯胺(1.58 g,18.7 mmol,1.50 equiv)及20%NaOH水溶液 (2.25 mL, 12.5 mmol, 1.00 equiv)之DMSO (12.5 mL)溶液中並將所得混合物在室溫下攪拌3.5小時。添加水(100 mL)同時用冰浴冷卻。於20分鐘後,將懸浮液過濾。將濾餅用水(3x40 mL)、EtOH (2x20 mL)及乙醚(2x20 mL)洗滌以產生呈無色固體之標題化合物(2.23 g,9.15 mmol,73%)。1
H NMR (300 MHz,丙酮-d6
) δ 7.63-7.56 (m, 1H), 7.38-7.23 (m, 2H), 7.17 (dd, J = 17.3, 11.0 Hz, 1H), 7.02 (s, 1H), 6.90-6.81 (m, 1H), 6.41 (s, 1H), 5.97 (s, 2H), 5.75 (dd, J = 17.3, 1.4 Hz, 1H), 5.54 (s, 2H), 5.38 (dd, J = 11.1, 1.3 Hz, 1H)。 b) 5-(二氟(苯基)甲基)-3-(2-乙烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7(4H)-酮將2,2-二氟-2-苯乙腈(629 mg,4.11 mmol,2.00 equiv)及K2
CO3
(1.42 g,10.3 mmol,5.00 equiv)添加至含5-胺基-1-(2-乙烯基苄基)-1H-1,2,3-三唑-4-甲醯胺(500 mg,2.06 mmol,1.00 equiv)之DMF(6.9 mL)溶液。將燒瓶封蓋並置於預熱至80℃之油浴中。於3小時後,添加另外的2,2-二氟-2-苯乙腈(157 mg,1.03 mmol,0.50 equiv)並將混合物在80℃下攪拌過夜。於冷卻至室溫後,添加水(10 mL)及2M HCl水溶液(5.2 mL)。將所得之懸浮液攪拌20分鐘及接著過濾。將濾餅用水(30 mL)、EtOH(30 mL)及乙醚(30 mL)洗滌,及乾燥以得到呈無色固體之標題化合物(357 mg,0.941 mmol,46%)。HRMS (ESI+) 380.1319 (M+H+
)。 c) 7-氯-5-(二氟(苯基)甲基)-3-(2-乙烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶將POCl3
(0.36 mL,3.9 mmol,2.0 equiv)添加至5-(二氟(苯基)甲基)-3-(2-乙烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-7(4H)-酮(0.74 g,2.0 mmol,1.0 equiv)及DMF (催化(cat.))含於甲苯(14.8 mL)與MeCN (14.8 mL)混合物中之溶液。將所得之混合物在80℃下攪拌6小時。添加另外的POCl3
(0.37 mL,4.0 mmol,1.0 equiv)並將混合物在80℃下攪拌過夜。於冷卻至室溫後,添加EtOAc (80 mL)。將溶液用水(30 mL)及鹽水(30 mL)洗滌。將有機物經MgSO4
乾燥並過濾及濃縮。在矽石上之急驟層析(10%EtOAc含於己烷)得到呈黃色固體之標題化合物(617 mg,1.55 mmol,80%)。HRMS (ESI+) 398.0986 (M+H+
)。 d) 5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3-(2-乙烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶將三乙胺(70 μL,0.50 mmol,2.5 equiv)添加至7-氯-5-(二氟(苯基)甲基)-3-(2-乙烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(80 mg,0.20 mmol,1.0 equiv)及3,3-二氟吡咯啶鹽酸鹽(35 mg,0.24 mmol,1.2 equiv) 含於CH2
Cl2
(2 mL)中之混合物。將所得之混合物在室溫下攪拌過夜。移除揮發物及使殘餘物接受在矽石上之急驟層析(10%EtOAc含於己烷)以得到呈無色油之標題化合物(91 mg,0.19 mmol,97%)。HRMS (ESI+) 469.1758 (M+H+
)。 e) 硫代乙酸S-2-((5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯乙基酯(S-2-((5-(Difluoro(phenyl)methyl)-7-(3,3-difluoropyrrolidin-1-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)methyl)phenethyl ethanethioate)將5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3-(2-乙烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(20 mg, 0.043 mmol, 1.0 equiv)與DMF (0.7 mL)、硫代乙酸(0.012 mL,0.17 mmol,4.0 equiv)及Bi2
O3
(0.2 mg,0.4 μmol,0.01 equiv)合併並用氮氣噴射混合物。添加BrCCl3
(0.4 μL,4 μmol,0.1 equiv)並將混合物用家用燈泡 (15 W)照射過夜。於添加EtOAc及水後,將層分離。將有機層用5% LiCl水溶液及鹽水洗滌。將有機物經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(10至40%EtOAc含於己烷)得到標題化合物(10 mg,0.018 mmol,43%)。HRMS (ESI+) 567.1549 (M+Na+
)。 f) 2-(2-((5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇將K2
CO3
(37 mg,0.26 mmol,2.0 equiv)添加至硫代乙酸S-2-((5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯乙基酯(72 mg,0.13 mmol,1.0 equiv)含於MeOH(1.0 mL)及THF(0.2 mL)之混合物中之溶液中。將所得反應混合物攪拌24小時。添加EtOAc (30 mL)。將有機物用2M HCl水溶液(20 mL)、水(20 mL)及鹽水(20 mL)洗滌。經MgSO4
乾燥及過濾後,移除溶劑以得到可按原樣用於隨後反應之標題化合物(64 mg,0.13 mmol,96%)。 g) 5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶 在-78℃,將2-(2-((5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇(20 mg,0.040 mmol,1.0 equiv)添加至含1-氯代苯并三唑(9.2 mg,0.060 mmol,1.5 equiv)及苯并三唑(4.7 mg,0.040 mmol,1.0 equiv)之CH2
Cl2
(0.4 mL)溶液並在-20℃下攪拌1小時。在-20℃下添加吡啶-2-硫醇(6.6 mg,0.060 mmol,1.5 equiv)並將混合物攪拌6小時。用Na2
S2
O3
水溶液及飽和NaHCO3
水溶液中止反應。將有機層分離並將水相用CH2
Cl2
(3x10 mL)萃取。將合併之有機物濃縮及使殘餘物接受製備型TLC (20%EtOAc含於己烷)以得到呈無色油之標題化合物(6.5 mg,0.001 mmol,27%)。HRMS (ESI+) 612.1613 (M+H+
)。實例 28 2-[2-[2-[[5-[ 二氟 ( 苯基 ) 甲基 ]-7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯基 ] 乙基二硫基 ] 乙醇 將碘(30 mg,0.12 mmol,3.0 equiv)分部分添加至2-巰基乙醇(0.014 mL,0.20 mmol,5.0 equiv)、吡啶(0.019 mL,0.24 mmol,6.0 equiv)及2-(2-((5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇(20 mg,0.040 mmol,1.0 equiv) 含於CH2
Cl2
(0.3 mL)及MeOH (0.1 mL)中之溶液。將所得混合物在室溫下攪拌2小時。添加EtOAc(20 mL)並將溶液用鹽水(10 mL)洗滌。將有機物經MgSO4
乾燥,過濾及濃縮。製備型TLC(5%EtOAc含於CH2
Cl2
)得到標題化合物(9 mg,0.02 mmol,39%)。HRMS (ESI+) 579.1613 (M+H+
)。實例 29 2-[2-[2-[[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯基 ] 乙基二硫基 ] 乙醇 a) 5-(第三丁基)-7-氯-3-(2-烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶將5-胺基-1-(2-烯基苄基)-1H-1,2,3-三唑-4-甲醯胺(1.00 g,4.11 mmol,1.00 equiv)溶解於二甲基乙醯胺(3.4 mL)中。添加吡啶(0.499 mL,6.17 mmol,1.50 equiv)及特戊醯氯(0.759 mL,6.17 mmol,1.50 equiv)。將所得混合物在85℃下攪拌5.5小時,然後添加KHCO3
(2.06 g,20.6 mmol,5.00 equiv)。將溫度升高至155℃並攪拌過夜。將反應混合物冷卻至室溫。添加水及將所得懸浮液過濾。將濾餅用乙醇及乙醚洗滌並乾燥以得到中間體三唑并嘧啶酮(1.22 g)。將中間體與MeCN (11.4 mL)、POCl3
(0.74 mL,7.9 mmol,2.0 equiv)及N,N
-二乙苯胺(0.63 mL,4.0 mmol,1.0 equiv)合併。將所得混合物在80℃下攪拌過夜。於冷卻至室溫後,添加EtOAc (80 mL)。用水(30 mL)及鹽水(30 mL)洗滌溶液,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(10%EtOAc含於己烷)得到呈黃色固體之標題化合物(847 mg,2.58 mmol,經兩個步驟63%)。HRMS (ESI+) 328.1327 (M+H+
)。 b) 5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3-(2-烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶將5-(第三丁基)-7-氯-3-(2-烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(847 mg,2.58 mmol,1.00 equiv)及3,3-二氟吡咯啶鹽酸鹽(445 mg,3.10 mmol,1.20 equiv)與CH2
Cl2
(25 mL)合併。添加三乙胺(0.90 mL,6.5 mmol,2.5 equiv)並將所得混合物在室溫下攪拌過夜。將揮發物移除及使殘餘物接受在矽石上之急驟層析(10%EtOAc含於己烷)以得到呈無色油之標題化合物(968 mg,2.43 mmol,94%)。HRMS (ESI+) 399.2101 (ESI+H+
)。 c) 硫代乙酸S-2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯乙基酯將AIBN (21 mg,0.13 mmol,0.10 equiv) 添加至含5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3-(2-烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(500 mg,1.26 mmol,1.0 equiv)及硫代乙酸(0.90 mL,13 mmol,10 equiv)之甲苯(5 mL)溶液。用氮氣淨化混合物10分鐘及在回流溫度下加熱過夜。添加另外的AIBN (21 mg,0.13 mmol,0.10 equiv)並使混合物再回流10小時。於冷卻至室溫後,添加EtOAc (100 mL)。用飽和碳酸氫鈉水溶液(2x40 mL)及鹽水(40 mL)洗滌溶液。將有機物經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(10%EtOAc含於己烷)得到標題化合物(393 mg,0.828 mmol,66%)。 d) 2-(2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇將硫代乙酸S-2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯乙基酯(100 mg,0.211 mmol,1.00 equiv)溶解於MeOH (4.0 mL)及THF(1.0 mL)中。添加K2
CO3
(58 mg,0.42 mmol,2.0 equiv)並將混合物攪拌過夜。添加EtOAc(40 mL)並用2M HCl水溶液(20 mL)、水(20 mL)及鹽水(20 mL)洗滌溶液。將有機物經MgSO4
乾燥,過濾及濃縮。粗硫醇無需進一步純化即可用於隨後的反應。 e) 2-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇 將碘(35 mg,0.14 mmol,3.0 equiv)分部分添加至2-巰基乙醇(0.016 mL,0.23 mmol,5.0 equiv)、吡啶(0.022 mL,0.28 mmol,6.0 equiv)及2-(2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇(20 mg,0.046 mmol,1.0 equiv)含於CH2
Cl2
(0.3 mL)及MeOH (0.1 mL)中之溶液。將所得混合物在室溫下攪拌8小時。添加EtOAc (20 mL)並用鹽水(10 mL)洗滌溶液。將有機物經MgSO4
乾燥,過濾及濃縮。製備型TLC(5%EtOAc含於CH2
Cl2
)得到標題化合物(4 mg,0.008 mmol,17%)。HRMS (ESI+) 509.1962 (M+H+
)。實例 30 3-[[2-[2-( 苯并三唑 -1- 基磺醯基 ) 乙基 ] 苯基 ] 甲基 ]-5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 將2-(2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇(15 mg,0.035 mmol,1.0 eq.)添加至含於CH2
Cl2
(0.3 mL)中之N-氯苯并三唑(8.0 mg,0.052 mmol,1.5 equiv)及苯并三唑(4.1 mg,0.035 mmol,1.0 equiv)並在-78℃下攪拌1小時。接著在-20℃下添加2-巰基乙醇(7 μL,0.1 mmol,1.5 equiv)並將混合物加熱至室溫。藉由添加Na2
S2
O3
水溶液及飽和NaHCO3
水溶液中止反應。將相分離及將水相用CH2
Cl2
(3x10 mL)萃取。將合併之有機層於真空中濃縮及使殘餘物接受製備型TLC(20%EtOAc含於己烷)以產生標題化合物(2 mg,3 μmol,10%)。HRMS (ESI+) 582.2206 (M+H+
)。實例 31 2-[2-[[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯基 ] 乙磺醯氟 在0℃下,將N-氯琥珀醯亞胺(20 mg,0.15 mmol,4.0 equiv)緩慢添加至硫代乙酸S-2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯乙基酯(18 mg,0.037 mmol,1.0 equiv)含於MeCN (0.6 mL)及2M HCl水溶液(0.12 mL,0.24 mmol,6.5 equiv)之混合物中之溶液。將所得溶液攪拌40分鐘。添加EtOAc(20 mL)及飽和NaHCO3
(20 mL)並將層分離。將有機相用鹽水(20 mL)洗滌,經MgSO4
乾燥,過濾及濃縮以得到粗磺醯氯,將其溶解於丙酮(0.5 mL)及水(0.025 mL)之混合物中。添加氟化鉀(10 mg,0.18 mmol,5.0 equiv)並在室溫下攪拌混合物6.5小時。添加EtOAc (20 mL)。將有機物用水(10 mL)及鹽水(10 mL)洗滌,經MgSO4
乾燥,過濾及濃縮。製備型TLC(20%EtOAc含於己烷)得到標題化合物(9 mg,0.02 mmol,53%)。HRMS (ESI+) 483.1780 (M+H+
)。實例 32 5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 )-3-[[2-[2-( 吡啶 -2- 基二硫基 ) 乙基 ] 苯基 ] 甲基 ] 三唑并 [4,5-d] 嘧啶 類似於針對5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶(實例27,步驟g)之合成所述之程序,自含於CH2
Cl2
(0.3 mL)中之2-(2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇(20 mg,0.046 mmol,1.0 equiv)、吡啶-2-硫醇(26 mg,0.23 mmol,5.0 equiv)、碘(35 mg,0.14 mmol,3.0 equiv)及吡啶(0.022 mL,0.28 mmol,6.0 equiv) 製備標題化合物及藉由製備型TLC進行單離(6 mg,0.01 mmol,24%)。HRMS (ESI+) 542.1972 (M+H+
)。實例 33 2-[2-[2-[[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯基 ] 乙基二硫基 ] 乙胺 類似於5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶(實例27,步驟g)之合成所述之程序,自含於CH2
Cl2
(1.0 mL)及MeOH (0.3 mL)中之2-(2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇(30 mg,0.069 mmol,1.0 equiv)、2-胺基乙硫醇(27 mg,0.35 mmol,5.0 equiv)、碘(53 mg,0.21 mmol,3.0 equiv)及吡啶(0.034 mL,0.42 mmol,6.0 equiv)製備標題化合物及藉由製備型TLC (20% MeOH含於CH2
Cl2
,1% NEt3
)單離呈油(5.5 mg,0.008 mmol,16%)。HRMS (ESI+) 508.2118 (M+H+
)。實例 34 2-[2-[2-[[5-[ 二氟 ( 苯基 ) 甲基 ]-7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯基 ] 乙基二硫基 ] 乙胺 類似於5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶(實例27,步驟g)之合成所述之程序,自含於CH2
Cl2
(0.5 mL)及MeOH (0.2 mL)中之2-(2-((5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇(20 mg,0.040 mmol,1.0 equiv)、2-胺基乙硫醇(15 mg,0.20 mmol,5.0 equiv)、碘(30 mg,0.12 mmol,3.0 equiv)及吡啶(0.019 mL,0.24 mmol,6.0 equiv) 製備標題化合物及藉由製備型TLC(20% MeOH含於CH2
Cl2
,1% NEt3
)單離呈油(4.5 mg,0.008 mmol,20%)。HRMS (ESI+) 578.1774 (M+H+
)。實例 35 3-[2-[2-[[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯基 ] 乙基二硫基 ] 丙烷 -1,2- 二醇 類似於2-[[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]甲基二硫基]乙醇(實例25,步驟b)之合成所述之程序,自硫代苯甲酸S-2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苄基酯(25 mg,0.058 mmol,1.0 equiv)及硫代甘油(9.4 mg,0.087 mmol,1.5 equiv)製備標題化合物及藉由製備型TLC(含40% EtOAc之CH2
Cl2
)單離呈無色油(22 mg,0.041 mmol,71%)。HRMS (ESI+) 539.2070 (M+H+
)。實例 36 2-[[2-[[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ] 苯基 ] 二硫基 ] 乙醇 a) 5-胺基-1-(2-碘苄基)-1H-1,2,3-三唑-4-甲醯胺類似於5-胺基-1-(2-乙烯基苄基)-1H-1,2,3-三唑-4-甲醯胺(實例27,步驟a)之合成所述之程序,自甲磺酸2-碘苄基酯(CAS 183789-20-0,6.67 g,21.4 mmol,1.00 equiv)製備標題化合物及單離呈無色固體(6.32 g,18.4 mmol,86%)。HRMS (ESI+) 344.0010 (M+H+
)。 b) 5-(第三丁基)-3-(2-碘苄基)-3H-[1,2,3]三唑并[4,5-b]吡啶-7(4H)-酮將5-胺基-1-(2-碘苄基)-1H-1,2,3-三唑-4-甲醯胺(0.500 g,1.46 mmol,1.00 equiv)溶解於二甲乙醯胺(2.4 mL)中。添加吡啶(0.18 mL,2.2 mmol,1.5 equiv)及特戊醯氯(0.27 mL,2.2 mmol,1.5 equiv)並將混合物在85℃下攪拌4小時。添加KHCO3
(1.01 g,7.29 mmol,5.0 equiv)並將混合物在155℃下攪拌過夜。將溶液冷卻至室溫。添加水(100 mL)及將所得懸浮液過濾。將濾餅用水(50 mL)、EtOH (50 mL)及乙醚(50 mL)洗滌及乾燥以得到呈無色固體之標題化合物(120 mg,0.293 mmol,20%)。HRMS (ESI+) 410.0467 (M+H+
)。 c) 5-(第三丁基)-7-氯-3-(2-碘代苄基)-3H-[1,2,3]三唑并[4,5-b]吡啶類似於7-氯-5-(二氟(苯基)甲基)-3-(2-乙烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(實例27,步驟c)之合成所述之程序,自5-(第三丁基)-3-(2-碘苄基)-3H-[1,2,3]三唑并[4,5-b]吡啶-7(4H)-酮(180 mg,0.440 mmol,1.00 equiv)製備標題化合物及單離呈無色固體(130 mg,0.304 mmol,69%)。HRMS (ESI+) 428.0128 (M+H+
)。 d) 5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3-(2-碘苄基)-3H-[1,2,3]三唑并[4,5-b]吡啶類似於5-(二氟(苯基)甲基)-7-(3,3-二氟吡咯啶-1-基)-3-(2-乙烯基苄基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(實例27,步驟d)之合成所述之程序,自5-(第三丁基)-7-氯-3-(2-碘苄基)-3H-[1,2,3]三唑并[4,5-b]吡啶(128 mg,0.299 mmol,1.00 equiv)製備標題化合物及單離呈無色油 (148 mg,0.299 mmol,99%)。HRMS (ESI+) 409.0908 (M+H+
)。 e) 硫代乙酸S-(2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-b]吡啶-3-基)甲基)苯基)酯將5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3-(2-碘苄基)-3H-[1,2,3]三唑并[4,5-b]吡啶(20 mg,0.040 mmol,1.0 equiv)溶解於甲苯(0.4 mL)中並用氮氣淨化。添加碘化銅(0.8 mg,4 μmol,0.1 equiv)、1,10-啡啉(1.5 mg,8.0 μmol,0.2 equiv)及硫代乙酸鉀(6.9 mg,0.060 mmol,1.5 equiv)並將混合物在100℃下攪拌19小時。添加水(20 mL)及EtOAc (20 mL)並將混合物攪拌5分鐘。將相分離及將水層用EtOAc (3x10 mL)萃取。將合併之有機層經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(10% EtOAc含於己烷)得到標題化合物(17 mg,0.038 mmol,95%)。HRMS (ESI+) 447.1771 (M+H+
)。 f) 2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-b]吡啶-3-基)甲基)苯硫醇類似於2-(2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)甲基)苯基)乙硫醇(實例29,步驟d)之合成所述之程序,自硫代乙酸S-(2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-b]吡啶-3-基)甲基)苯基)酯(61 mg,0.14 mmol,1.0 equiv)製備標題化合物及單離作為無需純化即可用於隨後步驟之粗產物(53 mg)。 g) 2-[[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]二硫基]乙醇 類似於2-[2-[2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇(實例28)之合成所述之程序,自粗製2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-b]吡啶-3-基)甲基)苯硫醇(20 mg,0.049 mmol,1.0 equiv)及巰基乙醇製備標題化合物及藉由製備型TLC (10% EtOAc含於CH2
Cl2
)單離(11 mg,0.023 mmol,46%)。HRMS (ESI+) 481.1645 (M+H+
)。實例 37 5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 )-3-[[2-( 吡啶 -2- 基二硫基 ) 苯基 ] 甲基 ] 三唑并 [4,5-d] 嘧啶
類似於針對2-[2-[2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇(實例28)之合成所述之程序,自粗製2-((5-(第三丁基)-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-b]吡啶-3-基)甲基)苯硫醇(30 mg,0.063 mmol,1.0 equiv)及2-巰基吡啶製備標題化合物及藉由製備型TLC (20% EtOAc含於己烷)單離(20 mg,0.034 mmol,46%)。HRMS (ESI+) 584.1312 (M+H+
)。實例 38 2-[[5- 第三丁基 -7-(3,3- 二氟吡咯啶 -1- 基 ) 三唑并 [4,5-d] 嘧啶 -3- 基 ] 甲基 ]-3- 乙炔基苯磺醯氟 a) 3-溴-2-甲苯-1-磺醯氟將3-溴-2-甲基-苯磺醯氯(CAS 886501-61-7,727 mg,2.70 mmol,1.00equiv)溶解於丙酮(8.5 mL)及水(0.5 mL)中。添加氟化鉀(783 mg,13.5 mmol,5.00 equiv)並將混合物在室溫下攪拌過夜。於氮氣流中移除大多數丙酮。將殘餘物分配在EtOAc(100 mL)與水(20 mL)之間。丟棄水相。將有機相用鹽水(20 mL)洗滌,經MgSO4
乾燥,過濾及濃縮以產生無色固體(628 mg,2.48 mmol,92%)。HRMS (MALDI+) 251.9250 (M+
)。 b) 2-甲基-3-((三甲基甲矽烷基)乙炔基)苯-1-磺醯氟將3-溴-2-甲苯-1-磺醯氟(628 mg,2.48 mmol,1.00 equiv)、Pd(PPh3
)Cl2
(174 mg,0.25 mmol,0.10 equiv)及CuI (71 mg,0.37 mmol,0.15 equiv)置於25 mL梨形瓶中。於排空及用氮氣(2x)回填後,添加MeCN (12.4 mL),接著添加DIPEA (867 μL,4.96 mmol,2.00 equiv)。使氮氣鼓泡通過黑色溶液5分鐘,然後添加TMS-乙炔(696 μL,4.96 mmol,2.00 equiv)。將燒瓶封蓋並置於預熱油浴(50℃)中。於3小時後,添加另外的TMS-乙炔(2.00 equiv)並在50℃下繼續攪拌過夜。於24小時後,將混合物冷卻至室溫,經矽藻土過濾及分配在水與EtOAc之間。用EtOAc (3x20 mL)萃取水相。用水及鹽水洗滌合併之有機相,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(0.7%EtOAc含於己烷)得到靜置時固化之棕色油(純度94%,610 mg,2.12 mmol,85%)。NMR分析表明約6%殘餘起始物質。HRMS (MALDI+) 270.0541 (M+
)。 c) 2-(溴甲基)-3-((三甲基甲矽烷基)乙炔基)苯-1-磺醯氟將2-甲基-3-((三甲基甲矽烷基)乙炔基)苯-1-磺醯氟(26 mg,0.096 mmol,1.00 equiv)與NBS(86 mg,0.48 mmol,5.00 equiv)、AIBN (2 mg,0.012 mmol,0.13 equiv)及MeCN (0.5 mL)合併。將混合物在80℃下攪拌過夜。將揮發物移除及藉由製備型TLC純化殘餘物以產生呈無色油之標題化合物(15 mg,0.043 mmol,48%)。HRMS (MALDI+) 370.9543 (M+Na+
)。(注意:反應永遠不會完成,若添加更多NBS/AIBN亦不會完成)。 d) 2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]-3-乙炔基苯磺醯氟 將2-(溴甲基)-3-((三甲基甲矽烷基)乙炔基)苯-1-磺醯氟(30 mg,0.086 mmol,1.00 equiv)與DMF(0.4 mL)、三甲胺(18 μL,0.13 mmol,1.5 equiv)及5-第三丁基-7-(3,3-二氟-吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶(CAS 1438465-59-8,27 mg,0.095 mmol,1.1 equiv)合併。於30分鐘後,用EtOAc (100 mL)稀釋混合物,用5% LiCl水溶液(2x20 mL)及鹽水(20 mL)洗滌,經MgSO4
乾燥,過濾及濃縮。在矽石上之急驟層析(5% EtOAc含於己烷)得到兩種區位異構之烷基化產物(14 mg)。將混合物溶解於THF (0.5 mL)中並添加三甲胺三氫氟化物(8.2 mg含於0.1 mL THF中,0.051 mmol,2.0 equiv)。於4小時後,用EtOAc (15 mL)稀釋混合物,用飽和碳酸氫鈉水溶液及鹽水(各3 mL)洗滌。經MgSO4
乾燥,過濾及濃縮得到粗物質,藉由pTLC(25%EtOAc含於己烷)純化粗物質以得到呈無色油之標題化合物(5 mg,0.011 mmol,經2個步驟13%)。HRMS (ESI+) 479.1474 (M+H+
)。實例 39 藥理 學 試驗
為測定式(I)之化合物之活性進行以下試驗:放射性配位體結合檢定
使用推薦量的表現人類CNR1或CNR2受體之人類胚腎(HEK)細胞之膜製劑(PerkinElmer)各自與1.5或2.6 nM作為放射性配位體之[3H]-CP-55,940 (Perkin Elmer)結合測定本發明化合物針對大麻素受體之親和力。於總體積0.2 mL之結合緩衝液(針對 CB1受體,50 mM Tris,5 mM MgCl2
,2.5 mM EDTA及0.5% (wt/vol)無脂肪酸BSA,pH 7.4及針對CB2受體,50 mM Tris,5 mM MgCl2
,2.5 mM EGTA及0.1% (wt/vol)無脂肪酸BSA,pH 7.4)中在30℃下振盪1小時進行結合。藉由通過經0.5%聚伸乙亞胺塗覆之微量過濾板(UniFilter GF/B濾板;Packard)快速過濾來終止該反應。使用非線性回歸分析(活性基礎, ID Business Solution, Limited) 分析結合放射性之Ki,其中自飽和實驗測定針對[3
H]CP55,940之Kd值。式(I)之化合物顯示針對CB2受體之優異親和力,其中親和力在10 µM以下,更特定言之1 nM至3 µM及最特定言之1 nM至100 nM。 根據式(I)之化合物具有特定言之0.5 nM至10 µM,更特定言之0.5 nM至3 µM及最特定言之0.5 nM至100 nM的以上檢定中之活性(Ki)。 所有化合物為具有3 µM以下之Ki值及於相應檢定中對CB1至少3倍之選擇性之CB2結合劑。 cAMP 檢定
在實驗之前17至24小時,將表現人類CB1或CB2受體之CHO細胞以每孔50.000個細胞接種於具有平坦透明底之黑色96孔板(Corning Costar #3904)的DMEM (Invitrogen No.31331)(補充1xHT與10%胎牛血清)中,並於加濕培養箱中在5% CO2
及37℃下培育。用含有1 mM IBMX之克雷伯(Krebs)林格氏碳酸氫鹽緩衝液交換生長培養基並在30℃下培育30分鐘。添加化合物至100 µL的最終檢定體積並在30℃下培育30分鐘。使用cAMP-Nano-TRF檢測套組,藉由添加50 µL溶解試劑(Tris,NaCl,1.5% Triton X100,2.5% NP40,10% NaN3
)及50 µL檢測溶液(20 µM mAb Alexa700-cAMP 1:1及48 µM釕-2-AHA-cAMP)停止該檢定(Roche Diagnostics)及在室溫下振盪2小時。藉由配備有ND:YAG雷射器作為激發源之TRF讀取器(Evotec Technologies GmbH)量測時差式能量轉移。利用在355 nm之激發及具有100 ns之延遲及100 ns之門閘之發射,各自在730 nm(頻寬30 nm)或645 nm(頻寬75 nm)總曝光時間10s,量測板兩次。如下計算FRET訊號:FRET = T730-Alexa730-P (T645-B645),其中P = Ru730-B730/Ru645-B645,其中T730為在730 nm處量測之試驗孔,T645為在645 nm處量測之試驗孔,B730及B645各自為在730 nm及645 nm處之緩衝液對照。自跨越10 µM至0.13 nM cAMP之標準曲線函數測定cAMP含量。 使用活性基礎分析(ID Business Solution, Limited)測定EC50
值。自該檢定產生之針對廣泛的大麻素激動劑之EC50
值與科學文獻公開之值一致。β- 抑制蛋白 (Arrestin) 轉位 檢定 –PathHunter™(DiscoveRx)
PathHunter™ β-抑制蛋白CHO-K1 CNR1細胞系(目錄編號#93-0200C2)及β-抑制蛋白CHO-K1 CNR2細胞系(目錄編號#93-0706C2) 係購自DiscoveRx公司。細胞系經工程改造以表現融合至β-抑制蛋白之β-半乳糖苷酶EA片段及融合至靶受體之ProLink互補肽。根據製造商之協定進行PathHunter™蛋白質互補試驗(DiscoveRx Corporation #93-0001)。使試驗板於384孔板(Corning Costar #3707,白色,透明底)中的20µL細胞接種試劑2 (Discoverx #93-0563R2A)中接種含有7500個(CNR1)及10000 個(CNR2)細胞。於37℃ (5% CO2
,95%相對濕度)下培育過夜後,添加5 μL試驗化合物(1%最終DMSO濃度)及在30℃下繼續培育90分鐘。接著添加檢測試劑(12 μL)並在室溫下繼續培育60分鐘。接著使用Victor3
V讀取器(Perkin Elmer) 分析板的化學發光訊號。 實例A 可以習知方式製造含有以下成分之膜衣錠劑:
使活性成分過篩並與微晶纖維素混合及將該混合物與含聚乙烯吡咯啶酮之水溶液造粒。接著將顆粒與羥基乙酸澱粉鈉及硬脂酸鎂混合並壓縮以各自產生120或350 mg之核。將核用以上提及之膜衣之水性溶液/懸浮液噴漆。實例 B
可以習知方式製造含有以下成分之膠囊:
使組分過篩並混合及將其填入2號膠囊。實例 C
注射液可具有以下組成:
將活性成分溶解於聚乙二醇400與注射用水(部分)之混合物中。藉由添加乙酸將pH調整至5.0。藉由添加殘餘量之水將體積調整至1.0 ml。過濾溶液,適當過量地填充小瓶中並滅菌。
Claims (16)
- 一種式(I)之化合物:(I) 其中 R1 為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自鹵磺醯基、鹵磺醯基烷基、異硫氰基烷基、異硫氰基、胺基烷基二硫基烷基、羥烷基二硫基烷基、羥烷基二硫基、胺基烷基二硫基、鹵素、烷基、吡啶基二硫基烷基、苯并三唑基磺醯基烷基、二羥烷基二硫基烷基及吡啶基二硫基之一個取代基取代及視情況進一步經氰基取代; R2 及R3 係獨立地選自氫、羥基、鹵素、硫羥基、硫羥基氮雜環丁烷基、疊氮基、異硫氰基及烷基二硫基; 限制條件為R1 、R2 及R3 中至少一者為含有磺醯基、異硫氰基、二硫基、硫羥基或疊氮基之基團; R4 為烷基或及苯基鹵烷基;且 n為0或1; 或其醫藥上可接受的鹽或酯。
- 如請求項1之化合物,其中R1 為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自鹵磺醯基、鹵磺醯基烷基、異硫氰基烷基、異硫氰基、鹵素、烷基、羥烷基二硫基烷基、吡啶基二硫基烷基、二羥基烷基二硫基烷基之一個取代基取代及視情況進一步經氰基取代。
- 如請求項1或2之化合物,其中R1 為選自苯基及[1,2,5]噁二唑基之環,其中該環經選自氟磺醯基、氟磺醯基甲基、異硫氰基甲基、異硫氰基、氯、甲基、羥乙基二硫基乙基、氟磺醯基乙基、吡啶基二硫基乙基、二羥基乙基二硫基乙基之一個取代基取代及視情況進一步經氰基取代。
- 如請求項1或2之化合物,其中R1 為氟磺醯基苯基、氟磺醯基甲基苯基、異硫氰基甲基苯基、異硫氰基苯基、氯苯基、甲基[1,2,5]噁二唑基、羥乙基二硫基乙基苯基、氟磺醯基乙基苯基、吡啶基二硫基乙基苯基、二羥乙基二硫基乙基苯基或(氟磺醯基)(氰基)苯基。
- 如請求項1或2之化合物,其中R2 為氫且R3 為羥基、硫羥基、疊氮基、異硫氰基或甲基二硫基或R2 及R3 同時均為氟。
- 如請求項1或2之化合物,其中R4 為第三丁基或苯基二氟甲基。
- 如請求項1或2之化合物,其中n為1。
- 如請求項1或2之化合物,其選自 2-({5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯-1-磺醯氟; (2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲磺醯氟; [2-({5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]甲磺醯氟; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶; (3S)-1-(5-第三丁基-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[(2-異硫氰基苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯-1-磺醯氟; 2-{[(2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲基]二硫基}乙-1-胺; 2-{[(2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲基]二硫基}乙-1-醇; 2-[(2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)二硫基]乙-1-醇; 2-[(2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)二硫基]乙-1-胺; 2-{[2-({5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]二硫基}乙-1-胺; 2-({[2-({5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]甲基}二硫基)乙-1-胺; 2-({5-[二氟(苯基)甲基]-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯-1-磺醯氟; 2-({5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯-1-磺醯氟; [2-({5-[二氟(苯基)甲基]-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]甲磺醯氟; [2-({5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯基]甲磺醯氟; (3S)-1-(5-[二氟(苯基)甲基]-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇; 5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-[(2-異硫氰基苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; 1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}氮雜環丁烷-3-硫醇; (3S)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; (3R)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; (3S)-1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; (3R)-1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇 7-(3-疊氮吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-第三丁基-3-[(2-氯苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-第三丁基-7-(3-異硫氰基吡咯啶-1-基)-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 7-(3-疊氮吡咯啶-1-基)-5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 7-(3-疊氮吡咯啶-1-基)-5-[二氟(苯基)甲基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 7-(3-疊氮吡咯啶-1-基)-3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-[二氟(苯基)甲基]-7-(3-異硫氰基吡咯啶-1-基)-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 2-[[5-[二氟(苯基)甲基]-7-[(3S)-3-羥基吡咯啶-1-基]三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟; 2-[[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]甲基二硫基]乙醇; 2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟; 5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶; 2-[2-[2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇; 2-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇; 3-[[2-[2-(苯并三唑-1-基磺醯基)乙基]苯基]甲基]-5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶; 2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙磺醯氟; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶; 2-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙胺; 2-[2-[2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙胺; 3-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]丙烷-1,2-二醇; 2-[[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]二硫基]乙醇; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[[2-(吡啶-2-基二硫基)苯基]甲基]三唑并[4,5-d]嘧啶;及 2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]-3-乙炔基苯磺醯氟。
- 如請求項1或2之化合物,其選自 2-({5-第三丁基-7-[(3S)-3-羥基吡咯啶-1-基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基}甲基)苯-1-磺醯氟; (2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯基)甲磺醯氟; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶; (3S)-1-(5-第三丁基-3-{[2-(異硫氰基甲基)苯基]甲基}-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基)吡咯啶-3-醇; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[(2-異硫氰基苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 2-{[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]甲基}苯-1-磺醯氟; 1-{5-第三丁基-3-[(2-氯苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; (3S)-1-{5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶-7-基}吡咯啶-3-硫醇; 7-(3-疊氮吡咯啶-1-基)-5-第三丁基-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-第三丁基-7-(3-異硫氰基吡咯啶-1-基)-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 5-[二氟(苯基)甲基]-7-[3-(甲基二硫基)吡咯啶-1-基]-3-[(4-甲基-1,2,5-噁二唑-3-基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 7-(3-疊氮吡咯啶-1-基)-3-[(2-氯苯基)甲基]-5-[二氟(苯基)甲基]-3H-[1,2,3]三唑并[4,5-d]嘧啶; 2-[[5-[二氟(苯基)甲基]-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯磺醯氟; 2-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]乙醇; 2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙磺醯氟; 5-第三丁基-7-(3,3-二氟吡咯啶-1-基)-3-[[2-[2-(吡啶-2-基二硫基)乙基]苯基]甲基]三唑并[4,5-d]嘧啶; 3-[2-[2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]苯基]乙基二硫基]丙烷-1,2-二醇;及 2-[[5-第三丁基-7-(3,3-二氟吡咯啶-1-基)三唑并[4,5-d]嘧啶-3-基]甲基]-3-乙炔基苯磺醯氟。
- 一種用於製備如請求項1至9中任一項之化合物之方法,該方法包括式(A)之化合物(A) 在式(B)之化合物及鹼之存在下之反應,(B) 其中R1 至R4 及n係如請求項1至7中任一項所定義。
- 如請求項1或2之化合物,其根據請求項10之方法製備。
- 如請求項1或2之化合物,其用作治療活性物質。
- 一種醫藥組合物,其包含依照請求項1至9中任一項之化合物及治療惰性載劑。
- 一種如請求項1至9中任一項之化合物之用途,其用於製備用於治療或預防疼痛、神經痛、動脈粥樣硬化、年齡相關之黃斑變性、糖尿病性視網膜病、青光眼、糖尿病、炎症、炎性腸病、局部缺血再灌注損傷、急性肝衰竭、肝纖維化、肺纖維化、腎纖維化、全身性纖維化、急性同種異體移植排斥、慢性同種異體移植腎病、糖尿病性腎病、腎小球性腎病、心肌病、心臟衰竭、心肌缺血/梗塞、全身性硬化病、燙傷、燒傷、肥厚性瘢痕、瘢痕瘤、齦炎發熱、肝硬化或腫瘤、骨質調節、神經退化、中風、短暫性腦缺血發作、葡萄膜炎、哮喘、骨質疏鬆症、精神性疾病、精神病、腫瘤學、腦炎、瘧疾、過敏症、免疫學病症、關節炎、胃腸疾病、類風濕性關節炎或過敏症之藥劑。
- 如請求項1或2之化合物,其用於治療或預防疼痛、神經痛、動脈粥樣硬化、年齡相關之黃斑變性、糖尿病性視網膜病、青光眼、糖尿病、炎症、炎性腸病、局部缺血再灌注損傷、急性肝衰竭、肝纖維化、肺纖維化、腎纖維化、全身性纖維化、急性同種異體移植排斥、慢性同種異體移植腎病、糖尿病性腎病、腎小球性腎病、心肌病、心臟衰竭、心肌缺血/梗塞、全身性硬化病、燙傷、燒傷、肥厚性瘢痕、瘢痕瘤、齦炎發熱、肝硬化或腫瘤、骨質調節、神經退化、中風、短暫性腦缺血發作、葡萄膜炎、哮喘、骨質疏鬆症、精神性疾病、精神病、腫瘤學、腦炎、瘧疾、過敏症、免疫學病症、關節炎、胃腸疾病、類風濕性關節炎或過敏症。
- 一種如請求項1至9中任一項之化合物之用途,其用於CB2受體之檢測或成像。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
??16175924.6 | 2016-06-23 | ||
EP16175924.6 | 2016-06-23 | ||
EP16175924 | 2016-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201811791A true TW201811791A (zh) | 2018-04-01 |
TWI764908B TWI764908B (zh) | 2022-05-21 |
Family
ID=56203225
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111101354A TWI824380B (zh) | 2016-06-23 | 2017-06-22 | 新穎[1,2,3]三唑并[4,5-d]嘧啶衍生物 |
TW106120830A TWI764908B (zh) | 2016-06-23 | 2017-06-22 | 新穎[1,2,3]三唑并[4,5-d]嘧啶衍生物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111101354A TWI824380B (zh) | 2016-06-23 | 2017-06-22 | 新穎[1,2,3]三唑并[4,5-d]嘧啶衍生物 |
Country Status (24)
Country | Link |
---|---|
US (1) | US10457685B2 (zh) |
EP (2) | EP4108665A1 (zh) |
JP (2) | JP6962942B2 (zh) |
KR (2) | KR102530131B1 (zh) |
CN (4) | CN113943297A (zh) |
AR (1) | AR108845A1 (zh) |
AU (2) | AU2017283136C1 (zh) |
BR (1) | BR112018075143A2 (zh) |
CA (2) | CA3023043A1 (zh) |
CL (1) | CL2018003610A1 (zh) |
CO (1) | CO2018011231A2 (zh) |
CR (2) | CR20220661A (zh) |
IL (2) | IL292015B1 (zh) |
MA (1) | MA45442A (zh) |
MX (1) | MX2018014684A (zh) |
MY (1) | MY197244A (zh) |
PE (1) | PE20190109A1 (zh) |
PH (1) | PH12018502733A1 (zh) |
RU (1) | RU2741597C2 (zh) |
SG (2) | SG10202113286RA (zh) |
TW (2) | TWI824380B (zh) |
UA (1) | UA123834C2 (zh) |
WO (1) | WO2017220517A1 (zh) |
ZA (1) | ZA201807133B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017220516A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
CN109311886B (zh) | 2016-06-23 | 2021-11-09 | 豪夫迈·罗氏有限公司 | [1,2,3]三唑并[4,5-d]嘧啶衍生物 |
EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
CN113387845B (zh) * | 2021-07-16 | 2022-12-20 | 国药集团化学试剂有限公司 | 一种苯甲基磺酰氟的制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003512326A (ja) * | 1999-10-18 | 2003-04-02 | ユニヴァーシティ オブ コネチカット | カンナビノイド相似インドール誘導体 |
JPWO2006051704A1 (ja) * | 2004-11-15 | 2008-05-29 | 大正製薬株式会社 | イミン化合物 |
EP1863778B1 (en) | 2005-03-31 | 2015-12-30 | Merck Sharp & Dohme Corp. | Spirocyclic thrombin receptor antagonists |
FR2887550A1 (fr) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique |
MX2008012400A (es) * | 2006-03-30 | 2008-10-10 | Irm Llc | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. |
US8629157B2 (en) * | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
EP2311443A1 (en) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
CN102924457A (zh) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | 三唑并嘧啶类衍生物、其制备方法及其用途 |
UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
US9067943B2 (en) | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
PE20151539A1 (es) | 2013-03-07 | 2015-10-28 | Hoffmann La Roche | Nuevos derivados de pirazol |
EP2991988B1 (en) | 2013-05-02 | 2017-05-31 | F. Hoffmann-La Roche AG | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
KR102330794B1 (ko) | 2013-05-02 | 2021-11-26 | 에프. 호프만-라 로슈 아게 | Cb2 수용체 작용제로서의 퓨린 유도체 |
EP3483163B1 (en) * | 2013-09-06 | 2021-06-23 | F. Hoffmann-La Roche AG | Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists |
EP3215506B1 (en) | 2014-11-07 | 2019-01-02 | F.Hoffmann-La Roche Ag | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 |
WO2017220516A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
CN109311886B (zh) | 2016-06-23 | 2021-11-09 | 豪夫迈·罗氏有限公司 | [1,2,3]三唑并[4,5-d]嘧啶衍生物 |
EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
-
2017
- 2017-06-20 MY MYPI2018002797A patent/MY197244A/en unknown
- 2017-06-20 PE PE2018003112A patent/PE20190109A1/es unknown
- 2017-06-20 SG SG10202113286RA patent/SG10202113286RA/en unknown
- 2017-06-20 BR BR112018075143-0A patent/BR112018075143A2/pt active Search and Examination
- 2017-06-20 SG SG11201809678VA patent/SG11201809678VA/en unknown
- 2017-06-20 UA UAA201900294A patent/UA123834C2/uk unknown
- 2017-06-20 KR KR1020187037004A patent/KR102530131B1/ko active IP Right Grant
- 2017-06-20 IL IL292015A patent/IL292015B1/en unknown
- 2017-06-20 KR KR1020237014572A patent/KR20230062680A/ko not_active Application Discontinuation
- 2017-06-20 CA CA3023043A patent/CA3023043A1/en active Pending
- 2017-06-20 RU RU2018146657A patent/RU2741597C2/ru active
- 2017-06-20 AU AU2017283136A patent/AU2017283136C1/en active Active
- 2017-06-20 CN CN202111184338.3A patent/CN113943297A/zh active Pending
- 2017-06-20 CN CN202210799583.3A patent/CN115073476A/zh active Pending
- 2017-06-20 CN CN202210807089.7A patent/CN115093418A/zh active Pending
- 2017-06-20 JP JP2018566249A patent/JP6962942B2/ja active Active
- 2017-06-20 MA MA045442A patent/MA45442A/fr unknown
- 2017-06-20 WO PCT/EP2017/064994 patent/WO2017220517A1/en active Application Filing
- 2017-06-20 MX MX2018014684A patent/MX2018014684A/es unknown
- 2017-06-20 CA CA3206921A patent/CA3206921A1/en active Pending
- 2017-06-20 EP EP22174808.0A patent/EP4108665A1/en active Pending
- 2017-06-20 CR CR20220661A patent/CR20220661A/es unknown
- 2017-06-20 EP EP17731149.5A patent/EP3475282B1/en active Active
- 2017-06-20 CN CN201780036295.XA patent/CN109348716A/zh active Pending
- 2017-06-20 CR CR20180615A patent/CR20180615A/es unknown
- 2017-06-21 AR ARP170101708A patent/AR108845A1/es unknown
- 2017-06-22 TW TW111101354A patent/TWI824380B/zh active
- 2017-06-22 TW TW106120830A patent/TWI764908B/zh active
-
2018
- 2018-10-19 CO CONC2018/0011231A patent/CO2018011231A2/es unknown
- 2018-10-25 ZA ZA2018/07133A patent/ZA201807133B/en unknown
- 2018-11-01 IL IL262711A patent/IL262711B2/en unknown
- 2018-12-14 CL CL2018003610A patent/CL2018003610A1/es unknown
- 2018-12-20 US US16/228,539 patent/US10457685B2/en active Active
- 2018-12-21 PH PH12018502733A patent/PH12018502733A1/en unknown
-
2021
- 2021-07-26 AU AU2021206925A patent/AU2021206925B2/en active Active
- 2021-10-14 JP JP2021168709A patent/JP7308246B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021206925B2 (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | |
US10450321B2 (en) | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | |
JP6669743B2 (ja) | カンナビノイド受容体2のアゴニストとしてのトリアゾロ[4,5−d]ピリミジン | |
US10457686B2 (en) | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | |
JP7090037B2 (ja) | 新規な[1,2,3]トリアゾロ[4,5-d]ピリミジン誘導体 | |
NZ747420A (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |